Удаляемый цветной гель, используемый в качестве индикаторного состава для оценки правильности воздействия инструментом на модели или муляжи органов тела человека

Настоящее изобретение относится к удаляемому цветному гелю, используемому в качестве индикаторного состава для оценки правильности воздействия инструментом на модели или муляжи органов тела человека, содержащему основу из карбоксиметилцеллюлозы, диэтиленгликоля и гидроксида натрия, глицерин, воду очищенную, ароматизатор, консерванты и краситель, при этом содержание компонентов на 100 г готового геля составляет: карбоксиметилцеллюлоза, г 15,9-17,5; диэтиленгликоль, мл 4,5-5,5; гидроксид натрия, г 10-11; глицерин, мл 5,8-6,5; вода дистиллированная, мл 50; ароматизатор, мл 4-4,5; консерванты, мл 5,4-6; краситель, мл 3,5-4. Техническим результатом настоящего изобретения является расширение области применения, возможность объективной оценки правильности воздействия инструментом на модели или муляжи органов тела человека и возможность многоразового использования. 3 з.п. ф-лы, 1 табл., 4 ил.

Полимерный материал медицинского назначения для эмболизации

Изобретение относится к области медицины и раскрывает материал медицинского и ветеринарного назначения, содержащий интерполимерный полиэлектролитный комплекс катионного полимера - полиалкилкарбоновой (полиакриловой или полиметакриловой) кислоты с анионным сополимером - N-винилпирролидона и 2-метил-5-винилпиридина или 4-винилпиридина или 2-винилпиридина. Эмболы из материала могут быть приготовлены предварительно в форме сферических и несферических частиц, вводимых в кровеносные сосуды в форме суспензии, или непосредственно внутри кровеносных сосудов (in situ) при совместном введении исходных компонентов. Дополнительно эмболы могут содержать химиотерапевтические и рентгеноконтрастные агенты. Материал характеризуется способностью к деструкции в результате воздействия электролитов и ферментативных систем организма человека и животных. Изобретение может быть использовано в качестве средства для эмболизации кровеносных сосудов с обратимым характером действия. 6 з.п. ф-лы, 2 табл., 4 пр., 1 ил ...

ОККЛЮЗИРУЮЩИЕ УСТРОЙСТВА НА ОСНОВЕ ПОЛИМЕРОВ, СИСТЕМЫ И СПОСОБЫ

... 1. Окклюзирующее устройство, содержащее: удлиненный элемент, имеющий первую компоновку и вторую компоновку, в котором первая компоновка имеет относительно малый проходной профиль, а вторая компоновка сложена, в котором удлиненный элемент имеет по меньшей мере одну модификацию для увеличения площади поверхности, поверхностного сопротивления и/или осевого профиля удлиненного элемента, и в котором, после введения альгината, удлиненный элемент в первой компоновке имеет первый объем, а во второй компоновке - второй объем, который больше первого объема.2. Устройство по п. 1, в котором по меньшей мере часть удлиненного элемента предрасположена ко второй компоновке.3. Устройство по п. 1, в котором удлиненный элемент не предрасположен ни к первой компоновке, ни ко второй компоновке и в котором вторая компоновка выбирается произвольно.4. Устройство по п. 1, в котором в первой компоновке удлиненный элемент является трубчатым и проходным, а во второй компоновке его проходимость ограничена наполнителем ...

АНТИТРОМБОТИЧЕСКИЙ МЕТАЛЛИЧЕСКИЙ МАТЕРИАЛ

Patterned surfaces

The present disclosure provides patterned materials that may be useful in reducing certain negative effects associated with damaged tissue in vivo. The patterned materials can modify the healing process, and may minimize the formation of scar tissue. Such effects can provide inhibition of adhesion between tissues and/or reduction of fibrotic encapsulation around implanted medical devices.

Implantable materials and methods for inhibiting tissue adhesion formation

SURGICAL NETWORK.

ANTIMICROBIAL ONE AND ANTIVIRAL ONE POLYMER MATERIALS

Agent for preventing organ adhesion and method for preventing adhesion using the same

Hydrogel

Disclosed is a hydrogel which comprises a polyanionic polysaccharide derivative with a hydrophobic group introduced by covalent bonding and a salt solution with a salt concentration of 50mM-200mM. The manufacturing method for the hydrogel includes: a step wherein a compound including a dilution of a hydrogel with an aggregated structure with an average particle size of 100-200nm, a polyanionic polysaccharide derivative with a hydrophobic introduced thereto, and a salt solution of 50-200mM is prepared; and a step wherein the compound is heat-treated. The hydrogel possesses long-term stability, and can be filtered through a porous filter with a pore diameter of 5m or greater.

Method of producing pleurodesis

The present invention provides methods of producing pleurodesis in a mammalian subject, comprising administration of a low dosage of a sclerosing agent such as silver or a salt of silver.

Coating agent and medical instrument surface treated with coating agent

The present invention provides a coating agent that has improved durability and a medical instrument (for example, a needle) that has been coated with said coating agent. This coating agent includes a hydroxyl-group-containing polyorganosiloxane (1) represented by general formula (1), a polydiorganosiloxane (2) represented by general formula (2), and an amino-group-containing polyorganosiloxane (3) represented by general formula (3). The mass ratio of the polydiorganosiloxane (2) to the amino-group-containing polyorganosiloxane (3) is 0.7-3.0. The hydroxyl-group-containing polyorganosiloxane (1) is included in a proportion of 2.4-5.5 mass% with respect to the total mass of the hydroxyl-group-containing polyorganosiloxane (1), the polydiorganosiloxane (2), and the amino-group-containing polyorganosiloxane (3).

Neuronal stimulation using electrically conducting polymers

SURGICAL MATERIALS SUITABLE FOR USE WITH BONE CEMENTS

SURGICAL MATERIALS SUITABLE FOR USE WITH BONE CEMENTS

A novel surgical network material is provided herein. It is made from physiologically acceptable filaments of resorbable organic polymers with a thickness of 50-300 .mu.n. The network which has an internal mesh width of 1-10 mm, can be used, in particular together with bone cements based on a prepolymer and a monomer, e.g. polyacrylates or polymethacrylates, in bone repair or other bone treatment.

POLYMER FILM, AND DISPERSION LIQUID AND AGGLOMERATE USING SAME

Provided are: a polymer film characterized in that the average film thickness T0 along a straight line D passing through the center of gravity of a two-dimensional maximum-area projection satisfies equation (a), the average value L of distances 1 from the center of gravity to edges satisfies equation (b), the Young's modulus E satisfies equation (c), and the thickness deviation ? defined by equation (d) satisfies equation (e); and a liquid dispersion and an agglomerate using the same. (a) 10 nm ? T0 ? 1000 nm, (b)0.1 µm ? L ? 500 µm, (c) 0.01 GPa ? E ? 4.3 GPa, (d) ?=1-T1/T2, (e) 0.346E×10-9-1.499 < ? < -0.073E×10-9+0.316. According to the present invention, a polymer film which is easy to handle and has excellent compatibility, coatability, adhesiveness, and adhesion with respect to organ tissues; and a liquid dispersion and an agglomerate using the same can be provided.

IN SITU FORMING HEMOSTATIC FOAM IMPLANTS

Systems and methods related to polymer foams are generally described. Some embodiments relate to compositions and methods for the preparation of polymer foams, and methods for using the polymer foams. The polymer foams can be applied to a body cavity and placed in contact with, for example, tissue, injured tissue, internal organs, etc. In some embodiments, the polymer foams can be formed within a body cavity (i.e., in situ foam formation). In addition, the foamed polymers may be capable of exerting a pressure on an internal surface of a body cavity and preventing or limiting movement of a bodily fluid (e.g., blood, etc.).

STENT APPARATUS

... [Problem] To reliably mount and hold a stent, with the diameter thereof reduced, on a balloon, said stent being obtained from a biodegradable polymer and being shape-memorized to a size such that the diameter expands to the internal diameter of a blood vessel or greater. [Solution] The invention is obtained from: a stent (2), which is a biodegradable polymer material formed into a tubular shape using polylactic acid having shape memory properties and which is shape-memorized to an expanded diameter size that supports a blood vessel from the inside when implanted inside said blood vessel; and a stent-holding member (3) obtained from a biodegradable polymer material, which covers said stent (2) from the outside and holds same with the diameter reduced compared to the shape-memorized size. A stent detection member (8) is installed on the stent (2) and a portion of the stent detection member (8) is fixed to the stent-holding member (3) to prevent the stent (2) from shifting position with respect ...

SUPERFINE POLYESTER FIBER AND TUBULAR SEAMLESS FABRIC

Provided is a superfine polyester fiber containing at least 98 wt% of a polyethylene terephthalate component, and characterized by fulfilling the following conditions: (1) the reduced viscosity (.eta.sp/c) is at least 0.80 dl/g; (2) the total fineness is 7-120 dtex, and the single filament fineness is no more than 0.5 dtex; and (3) the toughness parameter (X) indicated by formula (1) is at least 2.0, the tensile strength is at least 3.5 cN/dtex and the tensile elongation is at least 12%. X - (tensile strength × .sqroot.tensile elongation)/(total fineness × single filament fineness)... formula (1).

derivados de carboidratos de rapamicina, composição farmacêutica, método para o tratamento de uma doença tratável por rapamicina e dispositivo médico

TISSUE REINFORCING COMPOSITIONS, DEVICES AND METHODS OF USE

Methods for manipulating and/or reinforcing tissues are provided. The method includes applying a tissue reinforcement material to at least a portion of tissue to be manipulated and applying energy to one or both of the tissue reinforcement material and the tissue.

FISTULA BLOCKER

L'invention vise à créer un dispositif de traitement pour assainir des fistules, permettant de traiter ces dernières de manière la plus douce possible, tout en conservant le plus possible les fonctions des structures anatomiques adjacentes. A cet effet, on utilise un obturateur de fistule servant à assainir un conduit fistuleux, comportant un élément d'obturation en forme de bouchon, pouvant être introduit au moins partiellement dans un conduit fistuleux. Cet élément d'obturation présente une surface de contact qui s'étend au moins partiellement sur le côté périphérique, transversalement au sens d'introduction et peut être mise en contact avec la paroi d'un conduit fistuleux. L'élément d'obturation est pourvu d'un cordon d'application flexible, pouvant être introduit dans le conduit fistuleux et se présentant sous la forme d'un drain.

URETER REDRESSING DEVICE

This invention provides a ureter redressing device which corrects the snacking of the ureter and keeps it in a desired shape. The redressing device is prepared by implanting a shape memory member such as a shape memory alloy or a shape memory resin in a longitudinal direction in a catheter consisting of a rod-like elastic material such as silicone rubber. The catheter is equipped with heating means for heating the shape memory member. If necessary, a temperature sensor for detecting the temperature of the shape memory member may be implanted in the catheter. The catheter may be further equipped with a hollow for ease of bending, or side holes or recesses so that its tip can be bended particularly easily.

Embolization Device Constructed From Expansile Polymer

Devices for the occlusion of body cavities, such as the embolization of vascular aneurysms and the like, and methods for making and using such devices. The devices may be comprised of novel expansile materials, novel infrastructure design, or both. The devices provided are very flexible and enable deployment with reduced or no damage to bodily tissues, conduits, cavities, etceteras.

MEDICAL DEVICE AND HOLLOW FIBER MEMBRANE-BASED MEDICAL DEVICE

It is intended to provide a highly reliable medical device, for example, hollow fiber membrane-type medical device, which can effectively prevent the occurrence of dielectric breakdown in an electron beam irradiation sterilization step. The present invention provides a hollow fiber membrane-type medical device comprising: a container having an inner space molded with an insulating material; a filter medium loaded in the inner space; an inlet provided on a container wall surface defining the inner space and intended for fluid influx into the container; an outlet provided on the container wall surface defining the inner space and intended for fluid efflux from the container, wherein the inlet and/or the outlet have a portion consisting of a polymer material having volume resistivity of 5×1013 ·cm or smaller, and the medical device has been irradiated with an electron beam.

Rapamycin carbohydrate derivatives

This invention provides modified rapamycins that have specific monosaccharide(s), oligosaccharide(s), pseudosugar(s) or derivatives thereof attached through a linker to create rapamycin carbohydrate derivatives having enhanced pharmacokinetic and/or pharmacodynamic profiles. For example, administration of the rapamycin carbohydrate derivative results in altered pharmacokinetic profiles and reduced toxicities. Thus, the present invention provides compounds with characteristics that are distinct from other drugs in its class such as rapamycin.

Rapamycin carbohydrate derivatives

This invention provides modified rapamycins that have specific monosaccharide(s), oligosaccharide(s), pseudosugar(s) or derivatives thereof attached through a linker to create rapamycin carbohydrate derivatives having enhanced pharmacokinetic and/or pharmacodynamic profiles. For example, administration of the rapamycin carbohydrate derivative results in altered pharmacokinetic profiles and reduced toxicities. Thus, the present invention provides compounds with characteristics that are distinct from other drugs in its class such as rapamycin.

Planetary gear assembly for sputtering multiple balloon catheter distal ends

An apparatus includes an assembly and hollow templates. The assembly includes multiple hinges mounted thereon. The assembly is configured to rotate about a first axis, and each of the hinges is additionally configured to rotate about a respective second axis. The hollow templates are fitted on the respective hinges and are each configured to contain a balloon-based distal end of a medical instrument, each template having a patterned opening through which one or more electrodes are deposited on the distal end.

Embolization Device Constructed From Expansile Polymer

Devices for the occlusion of body cavities, such as the embolization of vascular aneurysms and the like, and methods for making and using such devices are described. 1. An occlusion device comprising:an expansile member having a solid mass and a substantially continuous length, anda flexible carrier member,wherein the expansile member includes a polyurethane polymer, andwherein the expansile member is within or on the flexible carrier member.2. The occlusion device of claim 1 , wherein the expansile member configured to expand upon a change in temperature.3. The occlusion device of claim 1 , wherein the expansile member configured to expand upon contact with an aqueous liquid.4. The occlusion device of claim 1 , wherein the flexible carrier member is a coil or microcoil.5. The occlusion device of claim 1 , wherein the expansile member includes at least one pH sensitive ionizable functional group.6. The occlusion device of claim 5 , wherein the at least one pH sensitive ionizable functional group includes a basic group or an acidic group.7. The occlusion device of claim 6 , wherein the basic group comprises an amine claim 6 , derivatives thereof claim 6 , or combinations thereof.8. The occlusion device of claim 6 , wherein the basic group is configured to be deprotonated at pHs greater than the pKa or protonated at pHs less than the pKa of the functional group.9. The occlusion device of claim 6 , wherein the acidic group comprises a carboxylic acid claim 6 , derivatives thereof claim 6 , or combinations thereof.10. The occlusion device of claim 6 , wherein the acidic group is configured to be protonated at pHs less than the pKa or de-protonated at pHs greater than the pKa of the functional groups.11. The occlusion device of claim 1 , wherein the expansile member is substantially free of acrylamide.12. The occlusion device of claim 1 , wherein the expansile member is biodegradable.13. The occlusion device of claim 1 , wherein the flexible carrier member is metallic or ...

Antimicrobial and antiviral polymeric materials

The invention provides an antimicrobial and antiviral polymeric material, having microscopic particles of ionic copper encapsulated therein and protruding from surfaces thereof.

METHOD FOR MASS TRANSFER OF MICRO-PATTERNS ONTO MEDICAL DEVICES

This invention is directed to a new method of mass-transfer/fabrication of micro-sized features/structures onto the inner diameter (ID) surface of a stent. This new approach is provided by technique of through mask electrical micro-machining. One embodiment discloses an application of electrical micro-machining to the ID of a stent using a customized electrode configured specifically for machining micro-sized features/structures. 1. A method of mass-transferring a micro-pattern onto a medical device , comprising the steps of:a. Providing an electrode having an outer surface, the electrode comprising a conducting material;b. Coating the outer surface of the electrode with non-conducting material to form a masked electrode;c. Defining the micro-pattern on an outer surface of the masked electrode;d. Mounting the medical device on the masked electrode, wherein an inner surface of the medical device is in contact with the outer surface of the masked electrode; ande. Transferring the micro-pattern onto the inner surface of the medical device by electrochemical micromachining.2. The method of claim 1 , wherein the electrode is comprised of a conducting material selected from the group consisting of stainless steel claim 1 , brass claim 1 , copper claim 1 , graphite claim 1 , molybdenum claim 1 , silver claim 1 , tungsten claim 1 , and platinum.3. The method of claim 1 , wherein the non-conducting material comprises a material selected from the group consisting of a polymer claim 1 , a ceramic claim 1 , and an oxide.4. The method of claim 1 , wherein the medical device is comprised of a material selected from the group consisting of stainless steel claim 1 , cobalt-chromium claim 1 , nitinol claim 1 , MP35N claim 1 , platinum-chromium claim 1 , and tantalum-titanium.5. The method of claim 1 , wherein the step of coating the electrode further comprises vacuum deposition.6. The method of claim 1 , wherein the step of defining the micro-pattern further comprises laser ablating ...

Automated Stent Coating Apparatus and Method

An automated apparatus and method for coating medical devices such as an intravascular stent, are disclosed in the method, a 2-D image of a stent is processed to determine (1) paths along the stent skeletal elements by which a stent secured to a rotating support element can be traversed by a dispenser head whose relative motion with respect to the support element is along the support-element axis, such that some or all of the stent skeletal elements will be traversed (2) the relative speeds of the dispenser head and support element as the dispenser head travels along the paths, and (3), and positions of the dispenser head with respect to a centerline of the stent elements as the dispenser head travels along such paths The rotational speed of the support and relative linear speed of the dispenser are controlled to achieve the desired coating thickness and coating coverage on the upper surfaces, and optionally, the side surfaces, of the stem elements ...

自動被覆装置および方法

ИНГИБИТОР ФИБРОЗА ТКАНЕЙ, В КОТОРОМ ИСПОЛЬЗУЕТСЯ БИОСОВМЕСТИМЫЙ ПОЛИМЕР

Группа изобретений относится к способу ингибирования фиброза тканей, включающему применение биосовместимого полимера и материала клеточного каркаса, где биосовместимый полимер фиксируют к одной ткани, фиброз которой подлежит ингибированию, и в другой ткани создают протез для области дефекта ткани с использованием материала клеточного каркаса, где биосовместимый полимер представляет собой фибрин или декстриновый гель, где материал клеточного каркаса представляет собой децеллюляризованную ткань, и где децеллюляризованная ткань представляет собой ткань, полученную посредством децеллюляризации биологической ткани, выбранной из группы, состоящей из подслизистой оболочки тонкого кишечника, перикарда и кожи, также относится к способу ингибирования фиброза тканей, включающему применение биосовместимого полимера и заменителя перикарда, где биосовместимый полимер фиксируют к одной ткани, фиброз которой подлежит ингибированию, и в другой ткани создают протез с использованием заменителя перикарда для ...

ЛИСТОВОЙ КОМПЕНСАТОР ТОЛЩИНЫ ТКАНИ

Группа изобретений относится к области медицины, а именно к медицинской технике и хирургии, и предназначена для компенсирования различий толщины ткани. Компенсатор толщины ткани содержит первый слой, содержащий первое лекарственное средство; второй слой, содержащий второе лекарственное средство; и третий слой, содержащий третье лекарственное средство, расположенный между первым слоем и вторым слоем. Также обеспечивается компенсатор толщины ткани, содержащий первый слой, содержащий первое лекарственное средство; второй слой, содержащий второе лекарственное средство; и емкость, содержащую третье лекарственное средство, находящееся в емкости. Использование группы изобретений позволяет доставлять множество различных или одинаковых лекарственных средств к целевой ткани, сохраняя возможность надлежащего захвата ткани. 2 н. и 13 з.п. ф-лы, 415 ил.

СПОСОБ И АППАРАТ ДЛЯ ПОЛУЧЕНИЯ СВЕРНУТОГО КОЛЛАГЕНОВОГО НОСИТЕЛЯ

Группа изобретений относится к получению свернутого коллагенового носителя. Представлен аппарат для получения свернутого коллагенового носителя, причем указанный аппарат содержит: устройство для нанесения влаги на коллагеновый носитель перед сворачиванием указанного коллагенового носителя; сворачивающее устройство, содержащее поворотное захватывающее средство для захвата коллагенового носителя вдоль края и сворачивания указанного коллагенового носителя; и поддерживающее устройство для поддержки коллагенового носителя при сворачивании. Указанный аппарат дополнительно содержит конвейерное устройство, которое перемещает коллагеновые носители перед сворачиванием через увлажняющее устройство и к сворачивающему устройству. Также представлены содержащее указанный аппарат производственное оборудование для получения свернутого коллагенового носителя и способ сворачивания коллагенового носителя. Достигается возможность получения коллагенового носителя, покрытого человеческим фибриногеном и человеческим ...

ПОЛИМЕРНЫЙ ГИДРОГЕЛЬ АКРИЛАМИДНОГО СОПОЛИМЕРА ТЕРАПЕВТИЧЕСКОГО ПРИМЕНЕНИЯ И СПОСОБ ЕГО ПОЛУЧЕНИЯ

Гидрогель представляет собой сополимер N-замещенного метакриламида или акриламида, сшивающего агента и соединения сахара или его производного, пептида, соединяющего ткань, или сопряженного полимера с антителами, причем полимер является гетерогенным, упругодеформирующимся и имеющим равновесное содержание воды, по крайней мере, около 80%. Он может быть использован для регенерации ткани и для восстановления органа, например, в развивающейся и зрелой нервной системе. Гидрогель обладает улучшенной способностью заживления ткани в тканевом образовании, которое достигается благодаря контролю над разрастанием клетки, инфильтрацией клетки и организацией ткани в стабильной полимерной матрице. 2 с. и 16 з.п. ф-лы, 4 ил.

Способ получения тромборезистентных изделий медицинского назначения

Изобретение относится к области медицины, а именно к созданию тромборезистентных медицинских изделий, и раскрывает способ получения тромборезистентных изделий медицинского назначения, выполненных из титана и сплавов на его основе. Согласно изобретению, изделия подвергаются обработке импульсным низкоэнергетическим сильноточным широкоапертурным электронным пучком прямой полярности, изделие находится под потенциалом катода. После этого осуществляется нанесение пленки a-C:H:SiOxс предварительной очисткой поверхности изделий ионным потоком в аргоновой плазме, обеспечивающей удаление оксидных соединений с поверхности и нагрев поверхности до температуры 170±20°С. Нанесение a-C:H:SiOxпленки осуществляется в смеси аргона и полифенилметилсилоксана при давлении 0,1 Па. Способ позволяет снижать количество адгезированных тромбоцитов на поверхности изделий медицинского назначения, а также позволяет улучшать медико-биологических свойств изделий, проявляющееся в отсутствии цитотоксичности по отношению ...

УСТРОЙСТВО ДОСТАВКИ ЛЕКАРСТВЕННОГО СРЕДСТВА, ПРИМЕНЯЕМОГО ПРИ РЕВМАТОИДНОМ АРТРИТЕ

... 1. Устройство для доставки лекарственного средства при ревматоидном артрите через дермальный барьер, содержащее:микроиглу и множество наноструктур, изготовленных на поверхности микроиглы, наноструктуры образуют заранее определенный узор; илекарственное средство при ревматоидном артрите, сообщающееся по потоку текучей среды с микроиглой.2. Устройство по п.1, в котором узор дополнительно содержит микроструктуры, причем наноструктуры обладают размером в сечении меньше, чем микроструктуры.3. Устройство по п.2, дополнительно содержащее вторые наноструктуры с размером в сечении меньше размера в сечении микроструктур и больше размера в сечении первых наноструктур.4. Медицинское устройство по п.1 или 2, в котором по меньшей мере участок наноструктур обладает размером в сечении меньше примерно 500 нанометров и больше примерно 5 нанометров.5. Медицинское устройство по п.1 или 2, в котором по меньшей мере участок наноструктур обладает промежутком между центрами наноструктур от примерно 50 нанометров ...

ПРЕДОТВРАЩАЮЩИЙ АДГЕЗИЮ МАТЕРИАЛ

... 1. Предотвращающий адгезию материал, по существу, состоящий из волокон соединения карбоксиметилцеллюлозы со щелочными металлами.2. Предотвращающий адгезию материал по п. 1, имеющий поверхностную плотность от 10 до 300 г/м.3. Предотвращающий адгезию материал по п. 1 или 2, имеющий молекулярную массу от 20000 до 2000000 Да.4. Карбоксиметилцеллюлозная структура, по существу, состоящая из карбоксиметилцеллюлоз, содержащих кислую карбоксиметилцеллюлозу и соединение карбоксиметилцеллюлозы со щелочными металлами в смешанном состоянии.5. Карбоксиметилцеллюлозная структура по п. 4, находящаяся в форме листа волокон, пленки или губки.6. Карбоксиметилцеллюлозная структура по п. 4, где период функционирования в организме составляет от 5 часов до 6 месяцев.7. Предотвращающий адгезию материал, содержащий карбоксиметилцеллюлозную структуру по любому из п.п. 4-6.8. Способ получения карбоксиметилцеллюлозной структуры по любому из п.п. 4-6, включающий кислотную обработку структуры соединения карбоксиметилцеллюлозы ...

ЛИСТОВОЙ КОМПЕНСАТОР ТОЛЩИНЫ ТКАНИ

... 1. Компенсатор толщины ткани, содержащий:первый слой, содержащий первое лекарственное средство;второй слой, содержащий второе лекарственное средство; итретий слой, содержащий третье лекарственное средство, расположенный между первым слоем и вторым слоем.2. Компенсатор толщины ткани по п. 1, в котором первое лекарственное средство, второе лекарственное средство и третье лекарственное средство независимо выбраны из гемостатического средства, противовоспалительного средства, антибактериального средства, антимикробного средства, антиадгезивного средства, противосвертывающего средства, фармацевтического действующего вещества, ингибитора матричных металлопротеиназ и их комбинаций.3. Компенсатор толщины ткани по п. 1, в котором первое лекарственное средство представляет собой гемостатическое средство, второе лекарственное средство представляет собой антиадгезивное средство, а третье лекарственное средство представляет собой ингибитор матричных металлопротеиназ.4. Компенсатор толщины ткани по п ...

IMPLANTIERBARES ACRYLAMIDE COPOLYMER HYDRAULIC GEL FOR THERAPEUTIC APPLICATIONS

MORE FISTELBLOCKER

RAPAMYCIN CARBOHYDRATE DERIVATIVES

BIOLOGICALLY DEGRADABLE FILM WITH HONEYCOMB STRUCTURE

IMPLANT FOR REINFORCING OF BONES AND FOR THE ANCHORAGE OF BONE SCREWS, IMPLANTS OR IMPLANT PARTS IN THE BONE.

ABSORBING MATERIAL FOR THE ADJUSTMENT OF FABRICS.

SURGICAL MATERIAL AND USE OF THE MATERIAL FOR THE PRODUCTION (A PART) OF AN ARRANGEMENT FOR USE IN THE BONE SURGERY.

Layered bioresorbable implant

ABSORBABLE MATERIAL FOR FIXATION OF TISSUES

ABSORBABLE MATERIAL FOR FIXATION OF TISSUES

Light-degradable material for producing disposable medical appliances

Device for delivery of rheumatoid arthritis medication

Disclosed are devices for delivering a rheumatoid arthritis drug across a dermal barrier. The devices include microneedles for penetrating the stratum corneum and also include structures fabricated on a surface of the microneedles to form a nanotopography. A random or non-random pattern of structures may be fabricated such as a complex pattern including structures of differing sizes and/or shapes. The pattern of structures on the surface of the microneedles may include nano-sized structures.

Device for fixing biological soft tissue, and method for producing same

The purpose of the present invention is to provide a device for fixing biological soft tissue, the device being composed of a magnesium-based alloy material, wherein the device is endowed with strength and deformation performance for being used as a device for coupling biological soft tissue that has been cut or separated due to an incision or the like during a surgical procedure, and is completely degraded in vivo and discharged after adhesion of the soft tissue or after healing of the incision tissue. This device, composed of a magnesium-based alloy material, is composed of a ternary Mg alloy material of Mg-Ca-Zn. In the Mg alloy material, the Ca and Zn are contained within the solid-solubility limit with respect to the Mg. The remainder is composed of Mg and unavoidable impurities. The Zn content is 0.5 at% or less. The Ca and Zn content has a relationship of Ca:Zn=l:x (where x is 1 to 3) by atom ratio. The crystal grain structure is equiaxed, the crystal grain size according to linear ...

DRUG COATING LAYER

The present invention is to provide a drug coating layer which has low toxicity and a high intravascular stenosis inhibitory effect, when delivering medical device coated with a drug into the body and medical device using the same. The drug coating layer is a drug coating layer having a morphological form including a plurality of elongate bodies having long axes that each crystal of a water-insoluble drug independently has on a substrate surface, in which the long axes of the elongate bodies are nearly linear in shape, and the long axes of the elongate bodies form an angle in a predetermined range with respect to a substrate plane with which the long axis of the elongate body intersects. Fig. 8 WO 2014/163091 PCT/JP2014/059665 [98] 50.0 ------------------------------------------------- 40.0 ------------------ ------------------------------- 30.0 -------------------- ----------------------------- (n 20.0-- ------- ------------------------------------- 10.0 ----------- -- ---------------- ...

POLYMER FILM AND ANTIADHESIVE MATERIAL USING THE SAME

An object of the present invention is to provide a polymer film that can be adjusted to movement or a fine uneven surface of a living body and has excellent ability to adhere to a biological tissue. The present invention provides a polymer film, comprising a block copolymer having a structure in which branched polyalkylene glycol and polyhydroxyalkanoic acid are bound to each other, wherein the polymer film has a film thickness of 10 to 1000 nm. The branched polyalkylene glycol has at least three terminal hydroxyl groups per molecule, the mass percentage of the branched polyalkylene glycol relative to the total mass of the block copolymer is 1% to 30%, and a value obtained by dividing the average molecular weight of polyhydroxyalkanoic acid in the block copolymer by X that is the number of terminal hydroxyl groups present per a single molecule of the branched polyalkylene glycol is 10000 to 30000.

ORGAN-ADHESION PREVENTING AGENT AND PROCESS FOR PREVENTING ADHESION USING THEREOF

An agent for preventing organ adhesion containing a .gamma.-polyglutamic acid chemically crosslinked substance as an active ingredient and a method f or preventing organ adhesion characterized by contacting or adhering the age nt for preventing organ adhesion to the local surface of, or as the case may be, around an organ whose postoperative adhesion is desired to prevent are disclosed. According to the invention, the adhesion of the surface of the or gan can be prevented effectively and the agent for preventing organ adhesion which is absorbed in the body, is highly safe, can be easily produced, and is highly practical, and the method for preventing organ adhesion using the same are provided.

SUPERFINE POLYESTER FIBER AND TUBULAR SEAMLESS FABRIC

Provided is a superfine polyester fiber containing at least 98 wt% of a polyethylene terephthalate component, and characterized by fulfilling the following conditions: (1) the reduced viscosity (?sp/c) is at least 0.80 dl/g; (2) the total fineness is 7-120 dtex, and the single fiber fineness is no more than 0.5 dtex; the toughness parameter (X) indicated by formula (1) is at least 2.0, the tensile strength is at least 3.5 cN/dtex, and the tensile elongation is at least 12%. X = (tensile strength ×vtensile elongation)/(total fineness × single fiber fineness) formula (1).

method and automated coating apparatus

TRANSPLANTATION MATERIAL FOR REGENERATING BIOLOGICAL TISSUE AND PROCESS FOR PRODUCING THE SAME

The object of the present invention is to promote adequate body tissue formation action in a body tissue filling material. The present invention provides a graft material for body tissue regeneration 1 provided with a tubular member 2 composed of a material that allows nutrients B to permeate to the outside from blood A that passes therein, a body tissue filling material 3 arranged around the periphery of the tubular member 2, and a film 4 composed of a biocompatible material that covers them.

BIOABSORBABLE STENT

УСТРОЙСТВО ДЛЯ ФИКСАЦИИ МЯГКОЙ БИОЛОГИЧЕСКОЙ ТКАНИ И СПОСОБ ЕГО ПРОИЗВОДСТВА

Изобретение относится к устройствам для фиксации мягкой биологической ткани. Устройство для фиксации мягкой биологической ткани выполнено из тройного магниевого сплава Mg-Ca-Zn, причем Ca и Zn содержатся в пределах концентрации твёрдого раствора на основе магния, остальное составляет Mg и неизбежные примеси, при этом содержание Zn составляет 0,5 ат.% или меньше, а атомное отношение Ca:Zn = 1:x, где х означает 1-3, а структура кристаллического зерна является равноосной и имеет средний размер кристаллического зерна 20-250 мкм. Способ производства устройства включает приготовления магниевого сплава, получение слитка, гомогенизирующую термическую обработку, горячее прессование, на котором осуществляют по меньшей мере одно горячее прессование в диапазоне температур от 250 до 450°C, отжиг в диапазоне температур 350-450°C, формование для придания устройству требуемой формы и очистку поверхности для удаления примесей. Изобретение направлено на получение биосовместимого устройства, материал которого ...

БИОСОВМЕСТИМЫЙ МАТЕРИАЛ

Изобретение относится к области медицинской техники, а именно к биосовместимому материалу, предназначенному для повышения жизнеспособности клеток костного мозга, на основе сплава никелида титана, отличающегося тем, что в состав сплава введено дополнительно серебро при полном ингредиентном содержании, в ат.%: серебро – 0.1-0.2; никель – 49.3-49.4; титан – остальное. Изобретение обеспечивает повышение биосовместимости материала. 1 пр., 1 ил.

Композиция для инъекций гиалуроновой кислоты, содержащей производное гиалуроновой кислоты и ДНК фракцию, и ее применение

Группа изобретений относится к области косметической промышленности и медицины, а именно к вводимой в виде инъекций композиции гиалуроновой кислоты для применения в косметических или терапевтических целях, содержащей производные гиалуроновой кислоты со степенью сшивания от 0,1 до 200% и ДНК фракции в количестве от 0,1 до 50% масс. в пересчете на общую массу композиции, где производные гиалуроновой кислоты со степенью сшивания от 0,1 до 200% получены с использованием сшивающего агента, содержащего две или более эпоксидных функциональных групп, а также относится к способу производства вводимой в виде инъекций композиции гиалуроновой кислоты, к композиции для дополнения биологической ткани, к вводимому в виде подкожных инъекций наполнителю, к композиции для лечения синдрома сухого глаза. Группа изобретений обеспечивает получение вводимой в виде инъекций композиции, обладающей прекрасными свойствами эластичности и силой выдавливания, при этом композиция обладает устойчивостью к действию фермента ...

РАСТВОРИМАЯ МИКРОИГЛА

Изобретение относится к медицинской технике, а именно к растворимой микроигле, содержащей иглы (101). Иглы выполнены из водорастворимого материала и смонтированы на одной стороне основания (102), представляющего собой листовой материал с полостями, проницаемыми для жидкости, подаваемой на основание. Иглы (101) смонтированы на основании (102) так, что нижняя часть игл (101) непосредственно соединена с основанием (102), и соединение нижней части игл (101) с основанием (102) обеспечено проникающей соединительной структурой. Нижняя часть игл (101) проникает в основание (102), занимая некоторые или все полости основания (102). Проникающая соединительная структура растворяется под действием жидкости, подаваемой на основание и проникающей в полости основания. Техническим результатом является реализация растворимой микроиглы удобной для применения конструкции, в которой проникающая структура, соединяющая иглы с основанием, может растворяться быстро и эффективно. 17 з.п. ф-лы, 9 ил., 1 табл.

СПОСОБ И АППАРАТ ДЛЯ ПОЛУЧЕНИЯ СВЕРНУТОГО КОЛЛАГЕНОВОГО НОСИТЕЛЯ

... 1. Аппарат для получения свернутого коллагенового носителя, причем указанный аппарат содержит- устройство для нанесения влаги на коллагеновый носитель перед сворачиванием указанного коллагенового носителя;- сворачивающее устройство, содержащее- поворотное захватывающее средство для захвата коллагенового носителя вдоль края и сворачивания указанного коллагенового носителя; и- поддерживающее устройство для поддержки коллагенового носителя при сворачивании.2. Аппарат по п. 1, причем захватывающее устройство содержит пару удлиненных элементов.3. Аппарат по п. 2, причем пара удлиненных элементов представляет собой пару пинцетов или щипцов.4. Аппарат по п. 1, причем поддерживающее устройство представляет собой полость, которая характеризуется наличием нижней части, выполненной в виде сегмента цилиндра, и по меньшей мере одного открытого конца, и при этом криволинейная часть сегмента цилиндра составляет по меньшей мере 180°.5. Аппарат по п. 4, причем полость сформирована в виде канала с двумя ...

Implantable materials and methods for inhibiting tissue adhesion formation

Described are materials and methods for inhibiting the formation of tissue adhesions. In one aspect, a prosthetic tissue support mesh, and especially such a mesh comprised of a remodelable material that promotes tissue ingrowth, incorporates an effective amount of an anti-inflammatory compound such as a non-steroidal anti- inflammatory drug (NSAID) to inhibit the formation of tissue adhesions to the mesh and/ or to surrounding tissues when implanted in a patient. Also described are materials and methods for increasing the length of persistence of implanted resorbable materials, and especially implanted bioremodelable materials, using an anti -inflammatory compound such as an NSAID.

Intraocular lens having a hard optic and a soft skirt

An intraocular lens for placement in a capsular bag, including a hard inner, optionally biconvex lens optic 12 and a soft pliable skirt 14 surrounding the lens optic. The lens optic 12 is a high refractive index material and may have a diameter of about 2-4 mm and may utilize a laser dissission yag space 32. The soft pliable skirt 14 with an inner circumference channel 20 secures about an edge 18 of the lens optic and may extend away at a downwardly sloping angle. The bottom edge 28 of the skirt can be continuous or intermittent, and can include a single or dual ridge barrier. The outer diameter of the lens skirt can be 6-9 mm. ...

COMPOSITIONS FOR MEDIZINHALTIGE SYRINGES

USE OF HYDROXYEICOSATETRAENSÄURE FOR INTRAOKULÄRE SURGERY

NEW RADICAL INHIBITOR WITH A VISCOELASTIC COMPOSITION; MANUFACTURING PROCESS AND PACKING

BONE FIXATION DEVICE

Polymer -based occlusion devices and systems

A method of occluding includes imbibing a porous elongate element (10) comprised of ePTFE with a calcium-containing solution. The method also includes delivering, via a delivery catheter (75), the calcium-imbibed porous elongate element to a target occlusion site. The method further includes administering, after the calcium-imbibed porous elongate element has been completely delivered to the target occlusion site and resides entirely within a volume defined by the target occlusion site, an alginate- containing solution to the target occlusion site.

Viscoelastic composition

The purpose of the present invention is to provide: a viscoelastic composition that has excellent manipulability and is suitable for uses in which, when an opaque dark liquid accumulates inside a tube and obstructs the field of view of an endoscope, the liquid is pushed away, securing the field of view of the endoscope; and a method for securing the field of view of an endoscope which involves using the viscoelastic composition. The viscoelastic composition for securing the field of view of an endoscope contains water and a substance exhibiting viscoelastic properties, preferably has a hardness of 550 N/m ...

Method and apparatus for enhancing the maturation rate of an arteriovenous fistula

A method and apparatus are aimed to improve arteriovenous fistula maturation rate by treating the fistula with a crosslink agent solution (fixative solution). The fixative solution will crosslink proteins and biomolecules, allowing formation of crosslinks that stabilize or stable tissue structure. The method and apparatus will address factors that contribute to arteriovenous fistula maturation failure by stopping the neointimal hyperplasia growth after vascular injury and stabilizing the venous wall to prevent the lumen from narrowing.

BIOABSORBABLE POLYLACTIDE BONE FIXATION DEVICE

A bone fixation device is disclosed. The device comprises an absorbable homopolymer of l-lactide or dl-lactide, or a copolymer of l-lactide, and a reinforcement material. The reinforcement material can be a particulate filler of hydroxyapatite or a plurality of fibers chosen from alumina, poly(p-phenylene terephthalimide), polyethylene terephthalate, and ultra high modulus polythene. These materials have the advantage that, apart from being bioabsorbable, they also show strength properties similar to normal bone, which is not the case with the stainless steel devices currently used.

POLYMER-BASED OCCLUSION DEVICES, SYSTEMS AND METHODS

A method of occluding includes imbibing a porous elongate element (10) comprised of ePTFE with a calcium-containing solution. The method also includes delivering, via a delivery catheter (75), the calcium-imbibed porous elongate element to a target occlusion site. The method further includes administering, after the calcium-imbibed porous elongate element has been completely delivered to the target occlusion site and resides entirely within a volume defined by the target occlusion site, an alginate- containing solution to the target occlusion site.

SCAFFOLD SYSTEM TO REPAIR CARDIOVASCULAR CONDITIONS

A device for treating a cardiovascular condition includes an expandable scaffold positionable in a portion of a vasculature of a mammal; and maintained via stent technology, wherein the scaffold is comprised of electrospun fibers composed of a biodegradable compound. The biodegradable compound serves as a temporary template that allows the cardiovascular tissue to be rebuilt about the scaffold.

SCAFFOLD SYSTEM TO REPAIR CARDIOVASCULAR CONDITIONS

A device for treating a cardiovascular condition includes an expandable scaffold positionable in a portion of a vasculature of a mammal; and maintained via stent technology, wherein the scaffold is comprised of electrospun fibers composed of a biodegradable compound. The biodegradable compound serves as a temporary template that allows the cardiovascular tissue to be rebuilt about the scaffold.

IMPLANTABLE ACRYLAMIDE COPOLYMER HYDROGEL FOR THERAPEUTIC USES

The hydrogel is a copolymer of an N-substituted methacrylamide or acrylamide, a cross-linking agent and a complex sugar or derivative, a tissue adhesion peptide or a polymer conjugate with antibodies, the polymer being heterogeneous, elastically deformable and having an equilibrium water content of at least about 80 %. It can be used for tissue regeneration and for organ repair, for example, in the developing and adult nervous system.

Therapeutic agent for solid cancer

ANTI-ADHESION COMPOSITION AND METHOD FOR MANUFACTURING ANTI-ADHESION AGENT COMPRISING SAME

The present invention relates to an anti-adhesion composition comprising gellan gum, chondroitin sulfate, and a gelling agent for ameliorating rapid decomposition, low viscosity, and low strength which are problems of an existing anti-adhesion agent, and for preventing adhesion between tissues. The present invention also relates to a method for manufacturing an anti-adhesion agent comprising the same. COPYRIGHT KIPO 2016 ...

ION COMPLEX MATERIAL HAVING FUNCTION OF INHIBITING ADHESION OF BIOLOGICAL SUBSTANCE AND METHOD FOR MANUFACTURING THE SAME

Antithrombotic free thrombus trapping equipment

The purpose of the present invention is to provide a free thrombus trapping equipment, which can trap the free thrombus surely and extend the available time by inhibiting the blood clotting reactions in the primary hemostasis stage concerns with blood platelet and the coagulation thrombus forming stage concerns with blood coagulation factor. The present invention provides a free thrombus trapping equipment, that immobilized a compound which is having ability of antithrombin to the surface, and provides a trapping method, which is including trapping the free thrombus using the free thrombus trapping equipment in blood of a living body.

METHOD FOR MASS TRANSFER OF MICRO-PATTERNS ONTO MEDICAL DEVICES

This invention is directed to a new method of mass-transfer/fabrication of micro-sized features/structures onto the inner diameter (ID) surface of a stent. This new approach is provided by technique of through mask electrical micro-machining. One embodiment discloses an application of electrical micro-machining to the ID of a stent using a customized electrode configured specifically for machining micro-sized features/structures.

Surgical materials suitable for use with bone cements

A surgical network material is made from filaments of resorbable organic polymers with a thickness of about 50-300 mu m and/or of non-resorbable filaments or wires with a thickness of 100-750 mu m. The network which has an internal mesh width of about 1-10 mm, can be used, in particular together with bone cements based on polyacrylates or polymethacrylates, in combating bone defects.

Suture needle

Strength of a front end part having a sharp point of a medical suture needle is maintained and resistance when piercing tissue is reduced. There is provided a medical suture needle having a triangular cross section made of austenitic stainless steel having a fibrously extending structure, having two first slanted surfaces (11) ground and sandwiching a ridge (20), and a bottom surface (13) sandwiched between the two first slanted surfaces and ground. The ridge is formed comprising a first cutting blade (1) that is formed by the two first slanted surfaces (11) intersecting, a ridge part (20) that is formed on a body part side of the first cutting blade without the first slanted surfaces (11) intersecting, and a second cutting blade (2) that is formed by two second slanted surfaces (12) ground, intersecting and sandwiching the first cutting blade (1) on a front end side of the first cutting blade (1). Length L2 of the first cutting blade is within a range of 3 to 20 times length L1 of the ...

Smart release system for growth factor delivery and combined bone and vascular growth

Embodiments of the present invention relate to structures and systems having a three-dimensional biomimetic structure with a porous biomimetic three-dimensional scaffold and a coating deposited onto a surface of the porous biomimetic three-dimensional scaffold as well as methods of using and fabricating the like.

АНТИТРОМБОТИЧЕСКИЙ МЕТАЛЛИЧЕСКИЙ МАТЕРИАЛ

Группа изобретений относится к области медицины, а именно к антитромбогенному металлическому материалу, в котором поверхность металлического материала покрыта покровным материалом, и к имплантируемому медицинскому устройству, выполненному из указанного антитромбогенного материала. Покровный материал включает производное фосфоновой кислоты или производное пирокатехина, которое связано с указанным металлическим материалом через соответственно фосфоновую группу или группу пирокатехина, а также ковалентно связано с полимером, имеющим средневесовую молекулярную массу 600-2000000 Да и содержащим в качестве составляющего мономера алкиленимин, виниламин, аллиламин, лизин, протамин или хлорид диаллилдиметиламмония, причем указанный полимер ионно связан с анионным соединением, имеющим антикоагулянтную активность и представляющим собой гепарин или производное гепарина. При этом отношение числа атомов азота и числа атомов серы к числу всех атомов по измерению XPS на поверхности антитромбогенного материала ...

СПОСОБ СОЗДАНИЯ ПЛЕВРОДЕЗА

... 1. Способ создания плевродеза у млекопитающего, содержащий введение субъекту, нуждающемуся в этом, серебра или соли серебра, общая доза которого составляет приблизительно от 5 до 500 мг за период введения.2. Способ по п.1, в котором общая доза составляет приблизительно от 10 до 450 мг.3. Способ по п.1, в котором общая доза составляет приблизительно от 10 до 300 мг.4. Способ по п.1, в котором период введения составляет приблизительно от 2 до 30 дней.5. Способ по п.1, в котором период введения составляет приблизительно от 3 до 10 дней.6. Способ создания плевродеза у млекопитающего, содержащий введение объекту, нуждающемуся в этом, серебра или соли серебра, средняя дневная доза которого составляет приблизительно от 0,005 мг/кг/в день до 2 мг/кг/в день на протяжении периода введения.7. Способ по п.6, в котором средняя дневная доза составляет приблизительно от 0,01 мг/кг/в день до 1 мг/кг/в день.8. Способ по п.6, в котором средняя дневная доза составляет приблизительно от 0,05 мг/кг/в день до ...

Способ получения композиционного биомедицинского материала «никелид титана-полилактид» с возможностью контролируемой доставки лекарственных средств

Изобретение относится к медицине, в частности к способу получения композиционного биомедицинского материала “никелид титана - полилактид” с возможностью контролируемой доставки лекарственных средств. Полилактид с молекулярной массой 45 кДа растворяют в хлороформе из расчета 3 грамма полимера в 100 мл хлороформа при температуре 80 °С в течение 1 часа при перемешивании. Затем в остывший до 30°С раствор полилактида добавляют лекарственное средство, в качестве которого используется Гентамицин, Цефотаксим, Линкомицин с концентрацией от 1 до 8 % вес. Измельчение и смешивание лекарственного средства в растворе осуществляют с помощью диспергатора при скорости 1000 об/мин в течение 30 минут. После чего наносят однородный раствор на проволоку из TiNi методом окунания, выдержки в течение 1 минуты и извлечения с последующей сушкой в течение 2-х суток на воздухе под вытяжкой при комнатной температуре 22 °С. Техническим результатом является получение покрытия заданной толщины и контролируемая биодеградация ...

СЛОЙ ЛЕКАРСТВЕННОГО ПОКРЫТИЯ

RAPAMYCIN-CARBOHYDRATE DERIVATE

Patterned surfaces

The present disclosure provides patterned materials that may be useful in reducing certain negative effects associated with damaged tissue in vivo. The patterned materials can modify the healing process, and may minimize the formation of scar tissue. Such effects can provide inhibition of adhesion between tissues and/or reduction of fibrotic encapsulation around implanted medical devices.

Fistula plugs having increased column strength andfistula plug delivery apparatus and methods

Tissue regeneration

Patterned surfaces

Cell coated implantable device

The present invention relates, in general, to a cell-coated implantable medical device and, in particular, to an implantable medical device the blood-contacting surfaces of which are coated with endothelial progenitor cells (EPCs). In a preferred embodiment, the medical device is a titanium or titanium alloy-based medical device.

Umbilical cord amniotic membrane products

Disclosed herein, in certain instances, are tissue grafts derived from UCAM. Further disclosed herein, in certain instances, are use for tissue grafts derived from UCAM.

Materials for soft and hard tissue repair

Biomaterials and methods and uses for repair or augmentation of tissues are provided. In particular, the invention provides a multi-layered, naturally occurring multi-axial oriented biomaterial comprising predominately type I collagen fibers. The invention further provides methods and uses for repair or augmentation of tissues using biomaterials of the invention.

Tissue thickness compensator comprising structure to produce a resilient load

A fastener cartridge assembly for an end effector of a surgical instrument can comprise a cartridge body, a deformable tube, and a fastener moveable between an initial position and a fired position. The deformable tube can be longitudinally positioned along a length of the cartridge body. When the fastener is moved to the fired position, the fastener can compress a portion of the deformable tube. The deformable tube can comprise a resilient material such that deformation of the deformable tube generates a restoring force. The deformable tube can comprise a lattice of strands woven together to form a tube wall. Further, the deformable tube can be bioabsorbable and can hold a therapeutic agent. The fastener cartridge assembly can comprise multiple, substantially parallel deformable tubes positioned side-by-side and/or within each other.

Polymer-Based Occlusion Devices, Systems and Methods

A method of occluding includes imbibing a porous elongate element comprised of ePTFE with a calcium-containing solution. The method also includes delivering, via a delivery catheter, the calcium-imbibed porous elongate element to a target occlusion site. The method further includes administering, after the calcium-imbibed porous elongate element has been completely delivered to the target occlusion site and resides entirely within a volume defined by the target occlusion site, an alginate-containing solution to the target occlusion site.

METHOD OF FABRICATING AN IMPLANTABLE MEDICAL DEVICE USING GEL EXTRUSION AND CHARGE INDUCED ORIENTATION

The invention provides a method of manufacturing a polymeric implantable medical device using gel extrusion of high molecular weight polymers or charge-induced orientation to avoid heat degradation of the polymer that might occur during conventional heat extrusion. 1. A method of manufacturing a stent , the method comprising:a. dissolving a matrix polymer having a number average molecular weight of at least 100,000 Da in a first solvent at a concentration such that a gel is formed;b. extruding the gel through an extrusion apparatus to form a tube or a sheet, wherein the temperature of the gel in the extrusion apparatus is at or about room temperature;c. quenching the formed tube or sheet in a second solvent that does not dissolve the matrix polymer but which allows the first solvent to diffuse out of the polymer;d. radially expanding and axially orienting the formed tube or biaxially orienting the formed sheet;e. drying the tubing or sheet; andf. forming the stent from the dried tubing or sheet.2. The method according to claim 1 , wherein the tube is axially oriented by deforming it to at least about 20 times its initial length.3. The method according to claim 1 , wherein the matrix polymer has a number average molecular weight of at least 500 claim 1 ,000 Da.4. The method according to claim 1 , wherein the matrix polymer has a number average molecular weight of at least 1 claim 1 ,000 claim 1 ,000.5. The method according to claim 1 , wherein the concentration of the polymer in the solvent is about 0.1 percent (w/w) to about 20% percent (w/w).6. The method according to claim 1 , wherein after forming the tubing or sheet from the polymer gel and drying the tube or sheet claim 1 , the average molecular weight of the matrix polymer is greater than 90% of its molecular weight prior to extrusion.7. The method of claim 1 , wherein the matrix polymer is selected from the group consisting of Poly(D claim 1 ,L-lactide); poly(L-lactide); poly(L-lactide-co-glycolide); poly (D ...

Injectable microspheres for dermal augmentation and tissue bulking

The present invention relates to elastic, hydrophilic and substantially spherical microspheres useful for dermal augmentation and tissue bulking. The invention provides injectable compositions comprising the microspheres and a biocompatible carrier for use in dermal augmentation. The present invention further provides methods of dermal augmentation and tissue bulking, particularly for the treatment of skin contour deficiencies, Gastro-esophageal reflux disease, urinary incontinence, and urinary reflux disease, using the injectable compositions.

Placental tissue grafts modified with a cross-linking agent and methods of making and using the same

Described herein are tissue grafts derived from the placenta that possess good adhesion to biological tissues and are useful in would healing applications. In one aspect, the tissue graft includes (1) two or more layers of amnion, wherein at least one layer of amnion is cross-linked, (2) two or more layers of chorion, wherein at least one layer of chorion is cross-linked, or (3) one or more layers of amnion and chorion, wherein at least one layer of amnion and/or chorion is cross-linked. In another aspect, the grafts are composed of amnion and chorion cross-linked with one another. In a further aspect, the grafts have one or more layers sandwiched between the amnion and chorion membranes. The amnion and/or the chorion are treated with a cross-linking agent prior to the formation of the graft. The presence of the cross-linking agent present on the graft also enhances adhesion to the biological tissue of interest. Also described herein are methods for making and using the tissue grafts.

Apparatus, system, and method for creating biologically protected/enhanced spaces in vivo

The present invention creates a biologically protected or enhanced space in vivo in a mammal to allow the mammal's immune system and/or other biological processes to function properly in order to treat autoimmune diseases. In particular, the biologically protected/enhanced space allows biological processes to occur that can therapeutically treat Type I diabetes. The biologically enhanced/protected space can also be used to promote growth of specific cells such as insulin producing islet cells of the pancreas. Microfluidic devices can also be used to remove soluble TNF receptors and autoreactive T Cells in treating autoimmune diseases. Additionally, microfluidic devices can be used to remove blood glucose, soluble insulin receptors and insulin-like growth factor (IGF) from blood in the treatment of adult onset (Type II) diabetes.

Acupressure medallion, method and device for its manufacture and method of reduction of pain from acupressure reflexotherapy

The acupressure element includes a base with spiked applicators and an additional layer of low-melting substance, which creates a surface flush with the points of the spiked applicators. The layer hides the points and prevents pain. During a reflexotherapy procedure, the layer of low-melting material melts, either under the influence of human body heat or with the use of external heating. The points of the spiked applicators are gradually released and begin to press on the skin. The pressure on the skin does not occur immediately, allowing to prepare for increased pain later and acclimate accordingly.

Synergistic Compositions and Devices for Gynecological Procedures

Synergistic compositions and medical devices for use in treatment during gynecological procedures are provided. A gynecological device for treatment of cervical blockages without general anesthesia thereby suitable for out-patient service, saving time and money to the patients is provided. Synergistic compositions that enable the practioners to perform gynecological procedures without pain or bleeding to the patients are provided. 1. A dilating device for unblocking cervix pathway , comprising the following parts;(a) a shaft with a head at one end and a threaded part at the other end,(b) a tubular structure as middle or connecting part covering the shaft,(c) a base or handle part,(d) a taper part to precede the middle part with provision(s) on its external surface to connect with a patch and{'i': 'Plantago ovato', '(e) a cone or patch.'}2. The device of claim 1 , wherein the central part of the shaft of the device between the head and the threaded part is unthreaded.3. The device of claim 1 , wherein the central part of the shaft comprises a plurality of bores.4. The device of claim 1 , wherein said central part of the shaft comprises means for fluid transmission claim 1 , a light source claim 1 , a fluorescent probe claim 1 , camera connectivity claim 1 , a surgical probe claim 1 , a drain provision to remove any undesired liquid claim 1 , during the procedure.5. The device of claim 2 , wherein said central part of the shaft is covered by a tubular structure claim 2 , to connect the taper part and base or handle part of the device having a smooth external surface and the tubular part is provided with a horizontal bore sufficient enough to allow the shaft to pass through.6. The device of claim 1 , wherein said base or handle part is tubular inside with a threaded part and an unthreaded part claim 1 , having external side tapered towards the head of the shaft claim 1 , with wider portion at the end to hold the device externally.7. The device of claim 5 , wherein said ...

MICRONEEDLE ARRAYS FOR ACTIVE AGENT DELIVERY

The present invention provides for microneedle arrays and related systems and methods. Particularly, microneedle arrays that are configured to deliver active agents, including nucleic acids and vaccines, are provided. Additional related methods of vaccinating and minimizing the amount of vaccine necessary for effective inoculation are also provided. 1. A method of providing visual verification of microneedle placement in a skin surface , comprising ,providing a microneedle array having a plurality of microneedles attached thereto, said microneedles including an indicatorapplying the microneedle array to a skin surface of a subject such that the microneedles are embedded into the skin surface,verifying successful application of the microneedles through observation of the indicator's presence in the skin.2. The method of claim 1 , wherein the indicator is a dye.3. The method of claim 1 , wherein the indicator forms an image on the skin of the subject.4. The method of claim 1 , wherein the indicator is visible when light is shown onto the microneedles.5. The method of claim 1 , wherein the indicator is a fluorophore.6. The method of claim 5 , wherein the flourophore includes fluorescein.7. A system for delivering siRNA to a subject claim 5 , comprising:an amount of a self-delivering siRNA a base, and', 'a plurality of microneedles attached to the base, said microneedles comprising a bioabsorbable/biodegradable material and being and configured to be detached from the base after being embedded in a skin surface., 'a microneedle array, said microneedle array comprising'}8. The system of claim 7 , wherein the microneedles include a plurality of longitudinal channels.9. The system of claim 8 , wherein the self-delivering siRNA are present in the longitudinal channels.10. The system of claim 7 , wherein the bioabsorbable/biodegradable material is selected from the group consisting of polyvinyl alcohol claim 7 , polyvinylpyrrolidone claim 7 , chitin claim 7 , carboxymethyl ...

TECHNIQUES FOR TREATMENT OF ABSCESSES

This document provides devices, system, and methods for treating an abscess cavity. For example, procedures that involve supplementing a biocompatible filler material with a therapeutic agent to promote tissue regeneration and healing are provided. The biocompatible filler materials that are treated with a therapeutic agent are implanted into the abscess cavity. The biocompatible filler material provides a tissue growth scaffold, and the therapeutic agent enhances tissue growth and healing. 1. A method for treating a fistula of a mammal , said method comprising:(a) obtaining a synthetic, bioabsorbable, non-woven material that is configured for implantation into the fistula,(b) soaking the material in a solution comprising adipose-derived stem cells and platelet derivative material for from about 1 hour to about 5 days, wherein the adipose-derived stem cells and platelet derivative material impregnate the material, thereby forming a treated material, and(c) implanting the treated material into the fistula.2. The method of claim 1 , wherein said mammal is a human.35-. (canceled)6. The method of claim 1 , wherein said fistula is an anal fistula.78-. (canceled)9. The method of claim 1 , wherein said soaking step comprises soaking the material in said solution for from about 18 hours to about 5 days.10. The method of claim 1 , wherein said soaking step comprises soaking the material in said solution for from about 1 day to about 5 days.11. The method of claim 1 , wherein said soaking step comprises soaking the material in said solution for from about 3 days to about 5 days. This application is a divisional of U.S. Ser. No. 14/435,778, filed Apr. 15, 2015, which is a National Stage application under 35 U.S.C. § 371 of International Application No. PCT/US2013/065631, having and International Filing Date of Oct. 18, 2013, which a claims the benefit of U.S. Provisional Application Ser. No. 61/715,506, filed Oct. 18, 2012. The disclosures of the prior applications are ...

Implantable device for the locationally accurate delivery and administration of substances into the pericardium or onto the surface of the heart

The present invention relates to a device for the administration of substances onto the epicardial surface of the heart. The device comprises a frame structure which is able to assume shaping, positioning, guiding and stabilizing functions. The frame structure may contain at least one sleeve. The device comprises a substance carrier which is able to accommodate the substance to be administered.

Methods of improving cell-based therapy

Provided are methods for improving cell-based therapies by co-administration with an agent that increases the production and or levels of epoxygenated fatty acids, as well as kits, stents and patches for co-administering stem cells with an agent that increases the production and/or levels of epoxygenated fatty acids.

Soft Tissue Pouch and Methods of Use Thereof

The invention relates to a soft tissue pouch and methods of use thereof. 1. A medical product comprising a medical device and a soft tissue pouch encapsulating the medical device.2. The medical product according to claim 1 , wherein the soft tissue is selected from skin claim 1 , dermis claim 1 , pericardium claim 1 , fascia claim 1 , arteries or veins claim 1 , dura mata claim 1 , ammonic membrane claim 1 , bladder claim 1 , small or large intestine.32. The medical product according to any of - claims 1 , wherein the soft tissue is an autograft claims 1 , an allograft claims 1 , or a xenograft.43. The medical product according to any of - claims 1 , wherein the soft tissue is dermis.54. The medical product according to any of - claims 1 , wherein the basement membrane side of the soft tissue is placed outward.65. The medical product according to any of - claims 1 , wherein the medical device is a pacemaker claims 1 , an ICD claims 1 , an insulin pump claims 1 , or an indwelling catheter.7. A method for preparing a soft tissue pouch for implanting a medical device into a patient claims 1 , comprising:(i) obtaining a mammalian soft tissue;(ii) optionally decellularizing and/or devitalizing the soft tissue;(iii) optionally treating the soft tissue with a plasticizer;(iv) suturing, stapling or gluing the soft tissue into a pouch shape configured to encapsulate a medical device;(v) packaging the soft tissue pouch in a packaging material; and(vi) optionally sterilizing the product.8. A method for implanting a medical device into a patient claims 1 , comprising(i) encapsulating the medical device into a soft tissue pouch;(ii) closing the opening of soft tissue pouch; and(iii) implanting the medical device with the soft tissue pouch.9. The method according to or claims 1 , wherein the soft tissue is selected from skin claims 1 , dermis claims 1 , pericardium claims 1 , fascia claims 1 , arteries or veins claims 1 , dura mata claims 1 , ammonic membrane claims 1 , bladder ...

NUCLEATED CELL PRESERVATION BY LYOPHILIZATION

The invention provides freeze-dried nucleated cells, a method for preparing them, and methods of using them for in vitro assays and in vivo therapeutic treatments. The method for preparing the cells includes incubating cells in the presence of a cryoprotective sugar to load them with the sugar, then lyophilizing them without separating the cells from the cryoprotective sugar. In embodiments, the cells are also loaded with one or more bioactive agents. 1. A population of freeze-dried nucleated cells , wherein said population , when rehydrated , has a viability level of at least 20%.2. The population of cells of claim 1 , wherein the population has a viability level of at least 25%.3. The population of cells of claim 1 , wherein the population has a viability level of at least 35%.4. The population of cells of claim 1 , wherein at least some of the cells comprise a bioactive agent.5. The population of cells of claim 4 , wherein the bioactive agent is an antibacterial agent claim 4 , an antiviral agent claim 4 , or an antifungal agent.6. The population of cells of claim 1 , wherein the cells are mammalian cells.7. The population of cells of claim 6 , wherein the cells are human cells.8. The population of cells of claim 6 , wherein the cells are blood cells.9. The population of cells of claim 8 , wherein the cells are B-cells claim 8 , T-cells claim 8 , or stem cells.10. The population of cells of claim 9 , wherein the stem cells are bone marrow stem cells.11. A method for preparing freeze-dried nucleated cells claim 9 , said method comprising:loading nucleated cells with a cryoprotectant in an aqueous environment;contacting the loaded cells with an excipient or bulking agent to create a lyophilization mixture; andlyophilizing the mixture,wherein the method does not include a separation step between loading of the cells and lyophilizing the cells.12. The method of claim 11 , further comprising claim 11 , prior to lyophilizing the mixture claim 11 , contacting the loaded ...

BARRIER LAYER

A barrier layer and corresponding method of making provide anti-inflammatory, non-inflammatory, and anti-adhesion functionality for a medical device implantable in a patient. The barrier layer can be combined with a medical device structure to provide anti-adhesion characteristics, in addition to improved healing, non-inflammatory, and anti-inflammatory response. The barrier layer is generally formed of a naturally occurring oil, or an oil composition formed in part of a naturally occurring oil, that is at least partially cured forming a cross-linked gel. In addition, the oil composition can include a therapeutic agent component, such as a drug or other bioactive agent. 145-. (canceled)46. A method of making a barrier layer device , the method comprising the steps of:providing a medical device structure; andcreating a barrier layer formed on at least a portion of the medical device structure; wherein the barrier layer is formed of a biological oil or oil composition comprising a cured fish oil, wherein the cured fish oil comprises fatty acids and glycerides, wherein two or more of the fatty acids are cross-linked to each other by ester bonds in a substantially random configuration, wherein the barrier layer is solid but flexible and serves as a physical barrier, and wherein the barrier layer degrades into non-inflammatory substances.47. The method of claim 46 , wherein creating the barrier layer comprises:providing a biological oil or oil composition;applying the oil or oil composition to the medical device structure; andcuring the oil or oil composition on the medical device structure to form the barrier layer.48. The method of claim 47 , further comprising partially curing the biological oil or oil composition prior to applying the oil or oil composition to the medical device structure to thicken the oil or oil composition.49. The method of claim 46 , further comprising applying the oil or oil composition using multiple tiers.50. The method of claim 46 , further ...

Adhesion Preventing Material

An object of the present invention is to provide an adhesion preventing material capable of preventing adhesion safely and efficiently. The present invention provides an adhesion preventing material comprised of a cell sheet containing mesothelial cells; an adhesion preventing method and organ regeneration promoting method each using the cell sheet containing mesothelial cells. 19-. (canceled)10. A method of preventing adhesion in a subject , comprising placing a cell sheet containing mesothelial cells on the surface or resected surface of a tissue or an organ of the subject.11. (canceled)12. (canceled)13. (canceled)14. The method of claim 10 , wherein the mesothelial cells are isolated from the subject.15. The method of claim 10 , wherein the mesothelial cells are isolated from an individual different from the subject.16. The method of claim 10 , wherein the mesothelial cells are isolated from an individual at fetal to infant stage.17. The method of claim 10 , wherein the mesothelial cells are liver mesothelial cells.18. The method of claim 10 , wherein the mesothelial cells are peritoneal mesothelial cells.19. The method of claim 10 , wherein the cell sheet does not comprise a support. The present invention relates to an adhesion preventing material consisting of a mesothelial cell sheet, and the like.In the context of an increase in the number of patients suffering from non-alcoholic steatohepatitis (NASH) or colon cancer patients due to westernization of lifestyle, the number of patients suffering from primary/metastatic liver cancer is expected to increase in future.As a treatment method for liver cancer which has a high recurrence rate, “repeated hepatectomy” has been accepted as one of the most effective methods which can extend the survival term or from which radical cure can be expected and it has been performed widely. The repeated hepatectomy however has a problem of postoperative adhesion. When postoperative adhesion occurs, adhesiotomy becomes necessary ...

PLASMA-BASED FILMS AND METHODS FOR MAKING AND USING THE SAME

The present invention relates to plasma-based films and in particular to flexible plasma-based films. The invention further relates to and to methods of making and using the flexible plasma-based films. Embodiments of the invention have been particularly developed for making flexible plasma-based films useful as a hemostat in the treatment and/or prevention of mild to severe as well as arterial bleedings, as an anti-adhesive sheet to reduce or prevent development of surgery-induced adhesions, as a wound healing patch, as a wound dressing, or as a film useful in hernia repair. Embodiments of the invention will be described hereinafter with reference to these applications. However, it will be appreciated that the invention is not limited to this particular field of use. 1. A flexible plasma-based film comprising between 0.1 to 10 International Units (IU) of thrombin per ml of plasma and having a thickness ranging from about 0.005 to 0.1 mm , wherein said flexible film is characterized by a fold number of at least 1 , such as at least 2 , such as at least 4 , such as at least 5.2. The flexible plasma-based film according to claim 1 , wherein said flexible film is characterized by a fold endurance of at least 10 claim 1 , such as at least 20 claim 1 , such as at least 30 claim 1 , such as at least 40 claim 1 , such as at least 50 claim 1 , such as at least 60 claim 1 , such as at least 70 claim 1 , such is at least 80 claim 1 , such as at least 90 claim 1 , such is at least 100.3. The flexible plasma-based film according to claim 1 , wherein said flexible film is characterized by a burst pressure of about 50 to 1000 mm Hg claim 1 , or of about 100 to 1000 mm Hg claim 1 , or of about 100 to 800 mm Hg claim 1 , or of about 100 to 600 mm Hg claim 1 , or of about 100 to 500 mm Hg claim 1 , or of about 100 to 450 mm Hg claim 1 , or of about 140 mm Hg claim 1 , or of about 150 mm Hg claim 1 , or of about 175 mm Hg claim 1 , or of about 200 mm Hg claim 1 , or of about 225 mm ...

Extracellular Matrix Tissue Prostheses

Tissue prostheses having a base structure and a physiological sensor system. The tissue prostheses are adapted and configured to induce remodeling of damaged tissue and regeneration of new tissue and concurrently detect and monitor physiological characteristics when implanted in the subject. 1. A tissue prosthesis , comprising:a base structure and a physiological sensor system, said physiological sensor system being joined to said base structure,said base structure comprising an extracellular matrix (ECM) composition comprising acellular ECM from a mammalian tissue source, said base structure, when disposed proximate damaged biological tissue, being adapted to induce modulated healing of said damaged tissue, said modulated healing comprising reducing an inflammatory phase of said damaged tissue and inducing host tissue proliferation, bioremodeling and, thereby, neovascularization of said damaged tissue, and regeneration of new tissue and tissue structures,said base structure and physiological sensor system being jointly adapted to concurrently induce said modulated healing and detect at least one physiological parameter of said subject, when disposed proximate said damaged biological tissue of said subject.2. The tissue prosthesis of claim 1 , wherein said mammalian tissue source comprises mammalian tissue selected from the group consisting of small intestine submucosa (SIS) claim 1 , urinary bladder submucosa (UBS) claim 1 , stomach submucosa (SS) claim 1 , urinary basement membrane (UBM) claim 1 , liver basement membrane (LBM) claim 1 , amniotic membrane claim 1 , mesothelial tissue claim 1 , placental tissue and cardiac tissue.3. The tissue prosthesis of claim 1 , wherein said ECM composition further comprises an additional biologically active agent.4. The tissue prosthesis of claim 3 , wherein said biologically active agent comprises a growth factor selected from the group consisting of a basic fibroblast growth factor (bFGF) claim 3 , transforming growth factor ...

DEVICE AND METHOD FOR SEALING A MEMBRANE

Disclosed embodiments relate to a membrane closure device () for closing a perforation in a membrane (), comprising: a patch guiding mechanism () for guiding at least one expandable patch () to a perforation site () of a membrane (); and a fastener delivery mechanism () for delivering a fastener () to the perforation site () and for fastening the at least one expandable patch by the fastener () to the membrane () to seal the perforation in the membrane () by the at least one expandable patch (). 110010100. A membrane closure device () for closing a perforation in a membrane () having a proximal side and a distal side , the membrane closure device () comprising:{'b': 120', '122', '150', '140, 'a patch () that is selectively expandable from a narrow to an expanded configuration and having in the expanded configuration a concave surface () defining a retention cavity () for receiving glue ();'}{'b': 110', '120', '10, 'a patch delivery mechanism () for guiding the patch () through a perforation of the membrane () from a proximal to a distal side thereof;'}{'b': 130', '330', '140', '140', '10', '120', '140', '10, 'a fastener delivery mechanism (, ) operable to contain glue () and further operable to deliver the glue () contained therein from the proximal side to the distal side of the membrane () for fastening the patch () in the expanded configuration, by the glue (), to the distal side of the membrane () to seal the perforation.'}2100150140130330. The membrane closure device () of claim 1 , wherein the retention cavity () defines a volume that is larger than a volume of glue () that can be contained claim 1 , at any given time claim 1 , by the fastener delivery mechanism ( claim 1 , ).31001201201610. The membrane closure device () according to claim 1 , comprising at least one tube having a distal and a proximal end for delivering the patch () in a folded configuration via the at least one tube from the distal to the proximal end for attaching the patch () in an ...

Implanted Device

Disclosed is an implanted device, comprising a device base body and an active drug, wherein the device base body is pure zinc and/or a zinc alloy, the zinc content in the device base body is 0.1-100%, and the active drug comprises anti-allergic drugs. After the implantation of the implanted device into the human body, the surrounding tissues of the implant would not have a clear hypersensitive reaction due to the presence of the anti-allergic drugs, and the implanted device can be used to be implanted into the body for supporting organ chambers, to fill the hollow chambers of the organs and tissues or as orthopaedic implants etc. 1. An implanted device , comprising a device substrate and an active drug , wherein the device substrate is pure zinc and/or a zinc alloy; the device substrate contains 0.1 to 100 percent of zinc; and the active drug comprises an anti-allergic drug.2. The implanted device according to claim 1 , wherein the implanted device further comprises a zinc complexing agent; wherein the zinc complexing agent and the pure zinc or the zinc alloy in the device substrate form a complex in body fluid.3. The implanted device according to claim 2 , wherein the zinc complexing agent contains at least one coordination group; the coordination group is selected from the group consisting of hydroxyl on polycyclic aromatic hydrocarbon claim 2 , sulfydryl claim 2 , amino claim 2 , an aromatic heterocyclic group claim 2 , nitroso claim 2 , carbonyl claim 2 , sulpho claim 2 , a phosphate group and an organic phosphorus group; the hydroxyl on the polycyclic aromatic hydrocarbon is a phenolic hydroxyl; and the aromatic heterocyclic group is selected from the group consisting of furyl claim 2 , pyrryl claim 2 , imidazolyl claim 2 , triazolyl claim 2 , thienyl claim 2 , thiazolyl claim 2 , pyridyl claim 2 , a pyridone group claim 2 , pyranyl claim 2 , a pyrone group claim 2 , pyrimidyl claim 2 , pyridazinyl claim 2 , pyrazinyl claim 2 , quinolyl claim 2 , isoquinolyl ...

Pouch-Like Structure with Paracrine Activity and Method for its Preparation

The present invention relates to a pouch-like structure useful for mechanically preventing distension and/or resisting dilation of the heart and for supporting the hearts function by controllable and paracrine support of a failing heart in a mammal. The pouch-like structure is composed at least partly of engineered tissue comprising genetically engineered cells, such as genetically engineered cells other than cardiac myocytes whereby said genetically engineered cell-scontain a gene encoding a paracrine factor, said gene encoding the paracrine factor being under control of an inducible promoter system or a heterologous promoter system. Further, the present invention relates to a method for the preparation of the pouch-like structure for therapeutic, disease modelling, and drug development applications. In addition, the present invention relates to cells other than cardiac myocytes for use in the preparation of the pouch-like structure as described herein. 19-. (canceled)10. A method for the preparation of a pouch-like structure suitable for enclosing at least a part of the heart of a mammal and comprising engineered tissue , said engineered tissue comprising genetically engineered cells wherein said cells contain a gene encoding a paracrine factor and said gene being under control of an inducible promoter system or a heterologous promoter system , comprising the steps ofa) providing a matrix having a recess in one surface of the matrix, said recess has appropriate dimensions to hold a defined reconstitution volume for the formation of the pouch-like structure,b) providing a body having dimensions corresponding to the desired dimensions of the interior of the pouch-like structure to be formed, and positioning the body in said recess of the matrix such that the body is spaced from the walls of said recess to form a space between the body and the walls of the recess corresponding to the reconstitution volume needed for formation of said pouch-like structure,c) ...

SMART RELEASE SYSTEM FOR GROWTH FACTOR DELIVERY AND COMBINED BONE AND VASCULAR GROWTH

Embodiments of the present invention relate to structures and systems having a three-dimensional biomimetic structure with a porous biomimetic three-dimensional scaffold and a coating deposited onto a surface of the porous biomimetic three-dimensional scaffold as well as methods of using and fabricating the like. 1. A three-dimensional biomimetic structure , comprising:a porous biomimetic three-dimensional scaffold; anda coating deposited onto a surface of the porous biomimetic three-dimensional scaffold,wherein the coating comprises a polymer network comprising a first biocompatible polymer, a second biocompatible polymer, a biologically active agent, and a cleavable cross-linking chemical compound,wherein each of the first biocompatible polymer and the second biocompatible polymer are reversibly cross-linked by the cleavable cross-linking chemical compound to each other or to the biologically active agent,wherein the biologically active agent is cross-linked to the polymer network when the cleavable cross-linking chemical compound is in an un-cleaved conformation, andwherein the biologically active agent is releasable from the polymer network when the cleavable cross-linking chemical compound is in a cleaved conformation.2. The three-dimensional biomimetic structure of claim 1 , wherein the porous biomimetic three-dimensional scaffold defines a first internal channel extending along a first axis and a second internal channel extending along a second axis claim 1 , andwherein the first internal channel and the second internal channel intersect.3. The three-dimensional biomimetic structure of claim 2 , wherein each of the first internal channel and the second internal channel has a diameter of between 100 μm to 1000 μm.4. The three-dimensional biomimetic structure of claim 1 , wherein the cleavable cross-linking chemical compound is cleavable by an enzyme or catalyst.5. The three-dimensional biomimetic structure of claim 1 , wherein the porous biomimetic three- ...

Drug coating layer

Provided are a drug coating layer which has low toxicity and a high intravascular stenosis inhibitory effect, when delivering medical device coated with a drug into the body and medical device using the same. The drug coating layer is a drug coating layer having a morphological form including a plurality of elongated bodies having long axes that each crystal of a water-insoluble drug independently has on a substrate surface, in which the long axes of the elongated bodies are nearly linear in shape, and the long axes of the elongated bodies form an angle in a predetermined range with respect to a substrate plane with which the long axis of the elongated body intersects.

COMPLIANCE CONTROL STITCHING IN SUBSTRATE MATERIALS

Compliance control stitch patterns sewn or embroidered into biotextile or medical textile substrates impart reinforcing strength, and stretch resistance and control into such substrates. Compliance control stitch patterns may be customizable to particular patients, substrate implantation sites, particular degenerative or diseased conditions, or desired time frames. Substrates having compliance control stitch patterns sewn or embroidered into them may be used in tissue repair or tissue reconstruction applications. 129-. (canceled)30. A method for repairing or reconstructing soft tissue in the body of a subject in need thereof , comprising implanting at a location in need of soft tissue repair or reconstruction an implant comprising a substrate comprising a biotextile , medical textile , or both a biotextile and medical textile , and one or more compliance control stitch patterns sewn or embroidered into the substrate.31. The method according to claim 30 , wherein the location comprises a hernia.32. The method according to claim 30 , wherein the location comprises a breast.33. The method according to claim 30 , wherein the substrate comprises a biotextile claim 30 , and the biotextile comprises an extracellular matrix.34. The method according to claim 33 , wherein the one or more compliance control stitch patterns comprise monofilament threads or yarns comprising polyethylene.35. The method according to claim 33 , wherein the one or more compliance control stitch patterns comprise threads or yarns comprising polypropylene.36. The method according to claim 33 , wherein the one or more compliance control stitch patterns comprise a plurality of lines comprising a plurality of repeating angles claim 33 , said lines oriented along one or more axes of the substrate.37. The method according to claim 36 , wherein the one or more compliance control stitch patterns is uniaxial.38. The method according to claim 36 , wherein the one or more compliance control stitch patterns is ...

ODOR NEUTRALIZING MASK INSERT

An air-permeable guard adapted to attach to a covering, the air permeable guard comprising a plurality of layers attached together to create one or more compartments. The guard further comprises at least one agent stored in the one or more compartments wherein the at least one agent may be a counteracting agent, a masking agent or a disinfectant agent. The masking agent may be coffee, oil and self encapsulated oil beadlet. The counteracting agent may be activated charcoal, sodium bicarbonate, zeolite, diatomaceous earth, silica gel and bentonite clay. The disinfectant agent may be a water based coating containing a cationic siloxane. In another embodiment of the invention the compartments may store the agents in a portion of the guard that is adapted to come in contact with the wearer's nostrils. 1. An air-permeable guard adapted to attach to a covering , the air permeable guard comprising:a plurality of layers attached together to create one or more compartments;at least one agent stored in the one or more compartments;and wherein the at least one agent may be a counteracting agent, a masking agent or a disinfectant agent.2. The air-permeable guard of wherein the covering is a surgical mask and wherein the air permeable guard is further adapted to fit a human face.3. The air-permeable guard of wherein the plurality of layers are comprised of one or material selected from the group consisting of paper claim 2 , cloth claim 2 , plastic claim 2 , or fiber.4. The air-permeable guard of wherein the the plurality of layers are attached together with an adhesive.5. The air-permeable guard of wherein the the plurality of layers are attached together by bond heating the plurality of layers.6. The air-permeable guard of wherein the the plurality of layers are attached together by stitching the plurality of layers.7. The air-permeable guard of wherein the plurality of layers comprises three or more layers wherein the three or more layers form two or more compartments.8. The ...

Embolization Device Constructed From Expansile Polymer

Devices for the occlusion of body cavities, such as the embolization of vascular aneurysms and the like, and methods for making and using such devices are described. 1. A device for implantation in an animal , comprising:a hydrogel having ionizable functional groups wherein said hydrogel comprises at least one macromer, further wherein said hydrogel is environmentally-responsive, and further wherein said hydrogel has an unexpanded bending resistance of about 0.1 mg to about 85 mg.2. A device according to claim 1 , wherein said macromer has a molecular weight of about 400 grams/mole to about 35 claim 1 ,000 grams/mole.3. A device according to claim 1 , wherein said hydrogel comprises polyethers claim 1 , polyurethanes claim 1 , derivatives thereof claim 1 , or combinations thereof.4. A device according to claim 1 , wherein said with ionizable functional groups comprise basic groups.5. A device according to claim 4 , wherein said basic groups comprise an amine claim 4 , derivatives thereof claim 4 , or combinations thereof.6. A device according to claim 5 , wherein said basic functional groups can be deprotonated at pHs greater than the pKa or protonated at pHs less than the pKa of said functional groups.7. A device according to claim 1 , wherein said with ionizable functional groups comprise acidic groups.8. A device according to claim 7 , wherein said acidic groups comprise a carboxylic acid claim 7 , derivatives thereof claim 7 , or combinations thereof.9. A device according to claim 8 , wherein said acidic functional groups can be protonated at pHs less than the pKa or de-protonated at pHs greater than the pKa of said functional groups.10. A device according to claim 1 , wherein said hydrogel comprises vinyl claim 1 , acrylates claim 1 , acrylamides claim 1 , methacrylates claim 1 , derivatives thereof claim 1 , or combinations thereof.11. A device according to claim 1 , wherein said macromer comprises poly(ethylene glycol) claim 1 , derivatives thereof claim 1 , ...

ANTI-INFECTIVE ANTIMICROBIAL-CONTAINING BIOMATERIALS

A material including a plurality of fatty acid chains cross-linked together and a silver fatty acid salt formed with the fatty acid chains within the material. Methods for forming a material are also included. The silver-containing materials can be utilized alone or in combination with a medical device for the release and local delivery of one or more anti-infective agents. 1. A material comprising:a plurality of fatty acid chains cross-linked together; anda silver fatty acid salt formed with the fatty acid chains within the material.2. The material of claim 1 , wherein the silver fatty acid salt is formed from an interaction between the fatty acid chains and an aqueous silver solution.3. The material of claim 2 , wherein the silver solution includes silver nitrate or silver acetate.4. The material of claim 1 , wherein the fatty acid chains are cross-linked together by at least partially curing an oil.5. The material of claim 1 , wherein the fatty acid chains are omega-3 fatty acids and the oil is a fish oil.6. A coating or film comprising the material of .7. The coating or film of having an additional antimicrobial compound applied to an outer surface of the coating or film.8. A method for forming a material claim 6 , comprising:at least partially curing a fatty acid biomaterial in order to cross-link chains of the fatty acid biomaterial together to form a bioabsorbable gel;soaking the bioabsorbable gel in an aqueous silver solution; andevaporating a solvent from the aqueous silver solution to form silver fatty acid salts within the bioabsorbable gel.9. The method of claim 8 , wherein the aqueous silver solution includes silver acetate or silver nitrate.10. The method of claim 8 , wherein the at least partially curing includes at least partially curing the fatty acid biomaterial onto a medical device.11. The method of claim 11 , wherein the medical device is a bandage claim 11 , a stent claim 11 , a graft claim 11 , a shunt claim 11 , a catheter claim 11 , a ...

ATRAUMATIC DETECTION/STIMULATION MICROLEAD

An atraumatic detection/stimulation lead is disclosed. The lead includes at least one microcable having a core cable comprising a plurality of elementary metal strands. One of the microcables has provided at its distal end an atraumatic protection device. The atraumatic protection device includes a protective coating on the distal ends of the elementary strands of the microcable, and the protective coating is covered by a protective cap of deformable material. The protective cap may be a conical distal end adapted to deform and axially flatten out. The microcable may have an overall diameter less than or equal to 1.5 French (0.50 mm). 1. An atraumatic lead for implantation in venous , arterial and lymphatic networks , comprising:at least one microcable, the microcable having a core cable comprising a plurality of elementary metal strands;wherein one of the at least one microcable is provided at its distal end with an atraumatic protection device comprising: (a) a protective coating on the distal ends of the elementary strands of the microcable; and (b) a protective cap of deformable material enveloping the protective coating.2. The lead of claim 1 , wherein the protective cap is made of incompressible material such that as the protective cap moves into contact with a venous wall claim 1 , the protective cap can axially flatten to provide a large surface area for distribution of pressure forces on the venous wall.3. The lead of claim 1 , wherein the protective coating has the shape of a sphere of homogeneous surface.4. The lead of claim 3 , wherein the diameter of the sphere is between 0.3 and 0.4 mm.5. The lead of claim 1 , wherein the protective coating is formed by melting the distal ends of the elementary metal strands.6. The lead of claim 1 , wherein the distal end of the protective cap is adapted to deform and axially flatten out.7. The lead of claim 1 , wherein a portion of the protective cap extends in proximal direction along the core cable in the form of a ...

METHOD FOR ELIMINATION OF SPACE THROUGH TISSUE APPROXIMATION

Acellular tissue matrix compositions for use in tissue approximation are provided. Also provided are methods for making and using the compositions to approximate tissue. 1. A method of approximating separated tissue , comprising:implanting particulate acellular tissue matrix into a space between two separated tissue planes, wherein the particulate acellular tissue matrix comprises decellularized fat tissue.2. The method of claim 1 , wherein implanting the acellular tissue matrix reduces the likelihood of formation of a seroma or hematoma within the space between the separated tissue planes.3. The method of claim 1 , wherein implanting the acellular tissue matrix promotes faster approximation of the separated tissue planes claim 1 , as compared to tissue approximation in the absence of an implanted acellular tissue matrix.4. The method of claim 1 , wherein the space is between two separated fat tissue planes.5. The method of claim 1 , wherein the space is between tissue planes comprised of different types of tissue.6. The method of claim 1 , wherein the particulate tissue matrix is derived from porcine tissue.7. The method of claim 1 , further comprising performing a surgical procedure to separate the two tissue planes.8. The method of claim 1 , wherein the particulate acellular tissue matrix contains less than 10% of the cells that normally grow within the tissue prior to decellularization.9. A method of approximating separated tissue claim 1 , comprising:implanting a foam comprising acellular tissue matrix into a space between two separated tissue planes, wherein the acellular tissue matrix comprises decellularized fat tissue, the foam produced by suspending acellular tissue matrix particles in a solution and freeze-drying the suspended particles in a mold.10. The method of claim 9 , wherein implanting the acellular tissue matrix reduces the likelihood of formation of a seroma or hematoma within the space between the separated tissue planes.11. The method of claim ...

DYNAMIC LOADING OF A THERAPEUTIC FLUID

The invention is directed to a method for therapeutic repair of an injury to bone or tissue comprising providing a structural component, wherein the structural component repairs the injury; and providing a therapeutic fluid, wherein the therapeutic fluid is located within the structural component. 1. A method for therapeutic repair of an injury to bone or tissue comprising:providing a structural component, wherein the structural component repairs the injury; andproviding a therapeutic fluid, wherein the therapeutic fluid is located within the structural component.2. The method of claim 1 , wherein the therapeutic fluid promotes repair of the injury.3. The method of claim 1 , wherein the therapeutic fluid comprises cells such as mesenchymal stem cells claim 1 , and proteins claim 1 , such as fibrinogen and growth factors. This Application claims the benefit under 35 U.S.C. §119(e) of U.S. Provisional Patent Application No. 61/717,482 filed Oct. 23, 2012 which is incorporated herein by reference in its entirety as if fully set forth herein.It is well known that the use of interference screws in surgical repairs of orthopedic injuries like an anterior cruciate ligament (ACL) repair or other ligamentous or tendonous repairs requiring anchoring devices can result in localized trauma to the bone in which the anchor or interference screw is placed. Trauma to the bone through which a screw is inserted in an ACL repair occurs due to the extremely tight fit of the screw threads as the screw is advanced through the tissue to tightly seal the tendons that are used to provide stability to the joint. There are issues related to the stability of highly compressed bone, due to potential necrosis of the compressed bone. Necrosis of the adjacent bony tissue could result in a reduction in the stability of the surgical repair, leading to a failure and a need for revision. Once an interference screw has been set in place, it is difficult or impossible to provide contact of the ...

IMPLANTABLE GRAPHENE MEMBRANES WITH LOW CYTOTOXICITY

Two-dimensional materials can be formed into enclosures for various substances and a substrate layer can be provided on an outside and/or on an inside of the enclosure, wherein the enclosure is not cytotoxic. The enclosures can be exposed to an environment, such as a biological environment (in vivo or in vitro), where the fibrous layer can promote vascular ingrowth. One or more substances within the enclosure can be released into the environment, one or more selected substances from the environment can enter the enclosure, one or more selected substances from the environment can be prevented from entering the enclosure, one or more selected substances can be retained within the enclosure, or combinations thereof. The enclosure can, for example, allow a sense-response paradigm to be realized. The enclosure can, for example, provide immunoisolation for materials, such as living cells, retained therein. 1. An enclosure comprising a compartment and a wall separating the compartment from an environment external to the compartment , wherein the wall comprises:a perforated graphene-based material layer anda substrate layer affixed directly or indirectly to the perforated graphene-based material,and wherein the enclosure is not cytotoxic when implanted into a subject.2. The enclosure of claim 1 , wherein the substrate layer comprises track-etched polyimide.3. The enclosure of claim 1 , wherein the substrate layer comprises a fibrous layer comprising a plurality of polymer filaments.4. The enclosure of claim 1 , wherein the compartment is in fluid communication with the external environment.5. The enclosure of claim 1 , wherein at least a portion of the wall is from about 5 nm to about 1 μm thick.6. The enclosure of claim 1 , further comprising at least one substance encapsulated within the compartment.7. The enclosure of claim 6 , wherein two or more substances are encapsulated within the compartment.8. The enclosure of claim 6 , wherein the substance comprises one or more ...

Hemostatic device

A hemostatic device, method of making, and method of using for internal and external applications to wounds in the body of a patient to induce hemostasis at an anatomical site.

Methods And Compositions For The Treatment Of Open And Closed Wound Spinal Cord Injuries

Devices and methods for the treatment of open and closed wound spinal cord injuries are disclosed. For example, described herein are devices and methods for mitigating secondary injury to, and promoting recovery of, spinal cord primary injuries. More particularly, certain embodiments of the present invention are directed to polymeric mini-tubes that may be used for the treatment of spinal cord injuries. In addition, other embodiments are directed to polymeric “fill-in” bandages that may be used for the treatment of spinal cord injuries. For example, an erodible, or biodegradable, form of biocompatible polymer of the present invention is fabricated for surgical implantation into the site of the spinal cord injury. 145-. (canceled)46. A method of treating a compression and/or contusion spinal cord injury in an animal comprising the steps of:(a) providing a suitably sized biodegradable and/or bioabsorbable polymeric article for implanting within a necrotic lesion of the spinal cord parenchyma tissue, wherein the polymeric article comprises a single layer scaffold; and(b) implanting the polymeric article within the lesion to bridge a gap in the spinal cord parenchymal tissue formed by said lesion wherein once implanted said polymeric article is not exposed to the environment outside the spinal cord.47. The method of claim 46 , wherein said polymeric article comprises a single layer linear aliphatic polyester scaffold.48. The method of claim 47 , wherein the linear aliphatic polyester is a polyglycolide or a co-polymer of poly(glycolide-co-lactide).49. The method of claim 46 , wherein the polymeric article degrades in vivo in 30 to 60 days.50. The method of claim 46 , wherein the polymeric article is a cylinder.51. The method of claim 46 , wherein the polymeric article is moldable.52. The method of claim 46 , wherein the polymeric article is tubular.53. The method of claim 46 , wherein the polymeric article further comprises one or more medicinal agents deposited onto ...

Novel Implantable Devices And Related Methods And Materials

The present invention provides implantable devices and related methods configured to stimulate, or otherwise modulate neural or other biological tissues or structures by implanting substance carrying devices and components such as micro-chips to promote, inhibit, alter, and otherwise affect and modulate the target structure's functionality, growth, expression, appearance and other features. 1. An implantable device implantable in humans , animals , plants , organs , tissues , tissue cultures , cell cultures , ova , gametes , eggs , hybrids , cells or organelles.2. The method of claim 1 , where the device consists of claim 1 , or contains one or more of preformed electrode claim 1 , diode claim 1 , lead claim 1 , circuit claim 1 , integrated circuit claim 1 , microcircuit claim 1 , MEMS claim 1 , wire claim 1 , micro wire claim 1 , array claim 1 , deployable array claim 1 , carbon fiber claim 1 , carbon claim 1 , carbon monolayer silicone claim 1 , metal claim 1 , rare metal claim 1 , structure claim 1 , circuit claim 1 , nanotubule claim 1 , or other microcircuit claim 1 , machine claim 1 , power generator claim 1 , power source claim 1 , microrotor claim 1 , magnet claim 1 , battery claim 1 , lead claim 1 , electrode claim 1 , sensor claim 1 , conduit for energy or electricity claim 1 , electromagnetic array claim 1 , generator of ultrasound claim 1 , radiowave claim 1 , radiation claim 1 , light claim 1 , laser claim 1 , maser claim 1 , or other energy claim 1 , engineered cell or cells claim 1 , biomanufactured organelle claim 1 , modified or native organ or organ component claim 1 , resevoir of chemotherapeutic agent claim 1 , radiotherapeutic agent claim 1 , sensor or RFID device or related device of MEMS claim 1 , nanomachine claim 1 , chip microchip claim 1 , electrode claim 1 , stimulator claim 1 , sensor.3. The method of claim 2 , where the device itself contains artificial or biologic components claim 2 , may include a collagen or collagen like substance ...

Method and apparatus for treating urethral stricture

A therapeutic device for treating a treatment area of a body lumen includes a delivery member possessing at least one attachment part, and a treatment membrane wrapped on the delivery member and detachably attached to the at least one attachment part of the delivery member

POLYMER LAMINATE

A polymer laminate has 2-100 layers each containing a biodegradable resin and having a thickness of 10 nm-400 nm that are laminated, the thickness of at least one of the outermost layers is 10 nm-180 nm, and the outermost layers are joined to each other. A polymer laminate excellent in biocompatibility and mechanical strength and suitable to medical applications such as wound dressings and antiadhesive materials can be obtained. 18.-. (canceled)9. A polymer laminate in which 2-100 layers each containing a biodegradable resin and having a thickness of 10 nm-400 nm are laminated , a thickness of at least one of outermost layers is 10 nm-180 nm , and said outermost layers are joined to each other.10. The polymer laminate according to claim 9 , wherein said at least one of outermost layers contains a polylactic acid-based resin.11. The polymer laminate according to claim 9 , wherein at least one layer of said layers having a thickness of 10 nm-400 nm contains a compound selected from the group consisting of a polysaccharide claim 9 , a polyvinyl alcohol and a polyvinyl alcohol copolymer.12. The polymer laminate according to claim 11 , wherein said polysaccharide is an alginate.13. The polymer laminate according to claim 9 , wherein a total thickness of the polymer laminate is 20 nm-1 claim 9 ,000 nm.14. The polymer laminate according to claim 9 , wherein a hydrophobic chemical is contained in at least one layer of said layers having a thickness of 10 nm-400 nm.15. The polymer laminate according to claim 9 , wherein a water soluble chemical is contained in at least one layer of said layers having a thickness of 10 nm-400 nm.16. The polymer laminate according to claim 9 , wherein particles having a particle diameter of 5 nm to 5 claim 9 ,000 nm are contained in at least one interlaminar part formed between said layers having a thickness of 10 nm-400 nm.17. The polymer laminate according to claim 10 , wherein at least one layer of said layers having a thickness of 10 nm- ...

Suture anchor with proximal end for promoting tissue in-growth

A suture anchor for tissue repair that has a proximal section and a main section where the proximal and main sections are formed of different materials. The proximal section is formed of a material that promotes in-growth from the surrounding tissue.

Organ Enclosures For Inhibiting Tumor Invasion And Detecting Organ Pathology

An enclosure provides a prophylactic barrier that may be permeable to gases, hormones, proteins, and peritoneal fluid, but restrains tumor cells within the enclosure so as to inhibit ovarian cancer invasion of adjacent tissue, and increase the speed of diagnosis of ovarian dysplasia, including cancer. The enclosure includes one or more of fiducial markers, heat sensors, and blood flow reflectors, which may be imaged non-invasively in order to detect conditions or pathology affecting the ovary. The enclosure may also include an access port that permits sampling of the enclosure's contents to further aid in detecting or treating conditions or pathology affecting the ovary. 1. A permanently implantable ovarian enclosure comprising:a biotextile, a medical textile, or both a biotextile and a medical textile;a suspensory ligament sleeve and an ovarian ligament sleeve; anda plurality of fiducial markers;wherein the enclosure has an elasticity that allows the enclosure to expand in size;wherein the biotextile, medical textile, or both the biotextile and the medical textile inhibit the passage of live ovarian cells out from the enclosure; andwherein the enclosure encloses an ovary.2. The enclosure according to claim 1 , wherein the enclosure comprises the biotextile claim 1 , and the biotextile comprises xenograft extracellular matrix.3. The enclosure according to claim 1 , wherein the enclosure comprises the medical textile claim 1 , and the medical textile comprises polypropylene claim 1 , polyethylene claim 1 , polyvinyl chloride claim 1 , polyurethane claim 1 , polyethylene terephthalate claim 1 , poly-L-lactide claim 1 , poly-DL-lactide claim 1 , polyglycolic acid claim 1 , poly(lactic-co-glycolic acid) claim 1 , polydioxanone claim 1 , polytetrafluoroethylene claim 1 , or nylon claim 1 , or any copolymer thereof.4. The enclosure according to claim 1 , wherein the enclosure comprises the medical textile claim 1 , and the medical textile comprises a silicone rubber or a ...

MEDICAL IMPLANT BASED ON NANOCELLULOSE

Medical Implant (), comprising 1. A method for producing a medical implant , comprising:providing a microbial cellulose tube, comprising a wall having an inner surface and an outer surface, wherein the wall comprises several layers of microbial cellulose, wherein said layers are concentric or substantially concentric to a longitudinal axis of the tube; and introducing a stent into the microbial cellulose tube to form the medical implant.3. A method according to claim 1 , further comprising expanding the microbial cellulose tube in a radial direction by inserting the tubular stent into the microbial cellulose tube.4. A method according to claim 3 , wherein the outer diameter of the stent before introducing the stent into the microbial cellulose tube is higher than the inner diameter of the microbial cellulose tube so that the microbial cellulose tube is expanded in one or more radial directions by the stent when the stent is introduced into the microbial cellulose tube.5. A method according to claim 1 , wherein the microbial cellulose tube is expanded by the stent in one or more radial directions (R).6. A method according to claim 5 , wherein the stent is removable from the cellulose tube claim 5 , further comprising removing the stent from the cellulose tube.7. A method according to claim 1 , wherein the stent is introduced such that an outer surface of the stent contacts the inner surface of the microbial cellulose tube.8. A method according to claim 1 , further comprising rotating the template having the liquid film around at least two rotational axes to equally distribute the film on the template and form the tube.9. A method according to claim 1 , further comprising stripping the tube from the template when separating the microbial cellulose from the template.10. A method according to claim 1 , further comprising purifying the tube.11. A method according to claim 1 , further comprising storing the tube in deionized water.12. A method according to claim 1 , ...

Gastrointestinal Device With Associated Microbe-Promoting Agents

A gastrointestinal device and methods of manufacturing said gastrointestinal device are described and include a flexible tubular structure including a layered wall, the flexible tubular structure including at least one microbe-promoting agent encased in the layered wall, the microbe-promoting agent configured to promote at least one of attraction, colonization, and growth of at least one type of commensal microbe, and a proximal end and a distal end, the proximal end and the distal end forming a flow conduit through the flexible tubular structure; and at least one anchor structure including one or more gastric wall-engaging components configured to engage a wall of the gastrointestinal tract of the subject. 1. A gastrointestinal device comprising: an inner surface and an outer surface;', 'at least one microbe-promoting agent associated with at least one of the inner surface and the outer surface, the at least one microbe-promoting agent configured to promote at least one of attraction, colonization, and growth of at least one type of commensal microbe; and', 'a proximal end and a distal end, the proximal end and the distal end forming a flow conduit through the flexible tubular structure; and, 'a flexible tubular structure including'}at least one anchor structure including one or more gastric wall-engaging components configured to engage a wall of the gastrointestinal tract of a subject.2. The device of claim 1 , wherein the flexible tubular structure is sized for placement in a portion of the gastrointestinal tract of the subject.3. The device of claim 1 , wherein the flexible tubular structure is a sleeve claim 1 , a liner claim 1 , or a stent.46.-. (canceled)7. The device of claim 1 , wherein the flexible tubular structure is formed from a semi-permeable material.814.-. (canceled)15. The device of claim 1 , wherein the flexible tubular structure is noncontiguous.16. The device of claim 1 , wherein at least a portion of the flexible tubular structure is degradable ...

METHODS FOR INCREASING A RETENTION FORCE BETWEEN A POLYMERIC SCAFFOLD AND A DELIVERY BALLOON

A medical device-includes a scaffold crimped to a catheter having an expansion balloon. The scaffold is crimped to the balloon by a process that includes inflating the delivery balloon during a diameter reduction to improve scaffold retention and maintaining an inflated balloon during the diameter reduction and prior and subsequent dwell periods. 115-. (canceled)16. A method for crimping , comprising the steps of:providing a scaffold comprising polymer characterized by a glass transition temperature (TG); and reducing the scaffold diameter from a first diameter to a second diameter,', 'removing the scaffold from the crimping mechanism,', 'placing the scaffold back into the crimping mechanism, wherein the scaffold is aligned between balloon markers when the scaffold is placed back into the crimping mechanism, and', 'reducing the scaffold diameter to a final diameter that is less than the second diameter,', 'wherein a ratio of the first diameter to the second diameter is greater than a ratio of the second diameter to the final diameter., 'using a crimping mechanism, crimping the scaffold to a balloon while the scaffold has a crimping temperature of between 5 to 15 degrees below TG including maintaining a pressure in the balloon as the scaffold diameter is being reduced in size, the crimping including'}17. The method of claim 16 , wherein the balloon pressure is maintained when the scaffold diameter is being reduced to the final diameter.18. The method of claim 17 , wherein the ratio of the starting diameter to the intermediate diameter is about 50% and the ratio of the intermediate diameter to the final diameter is about 30%.19. The method of claim 18 , wherein the crimping temperature is about 48° C.20. The method of claim 16 , wherein a final crimped diameter for the scaffold has a retention force that is greater than 1.0 lbs claim 16 , the scaffold has a length of no more than 18 mm and the final diameter is at least 2.5 times less than the starting diameter.21. ...

Gastrointestinal Device With Associated Microbe-Promoting Agents

A gastrointestinal device and methods of manufacturing said gastrointestinal device are described and include a flexible tubular structure including an inner surface and an outer surface, at least one microbe-promoting agent associated with at least one of the inner surface and the outer surface, the at least one microbe-promoting agent configured to promote attraction, colonization, and growth of at least one type of commensal microbe, and a proximal end and a distal end, the proximal end and the distal end forming a flow conduit through the flexible tubular structure; and at least one anchor structure including one or more gastric wall-engaging components configured to engage a wall of the gastrointestinal tract of the subject.

Adhesion Preventing Material

An object of the present invention is to provide an adhesion preventing material capable of preventing adhesion safely and efficiently. The present invention provides an adhesion preventing material comprised of a cell sheet containing mesothelial cells; an adhesion preventing method and organ regeneration promoting method each using the cell sheet containing mesothelial cells. 1. An adhesion preventing material consisting of a cell sheet comprising mesothelial cells.2. The adhesion preventing material according to claim 1 , wherein the mesothelial cells are cells derived from the same individual as the subject of the adhesion prevention.3. The adhesion preventing material according to claim 1 , wherein the mesothelial cells are cells derived from an individual different from the subject of the adhesion prevention.4. The adhesion preventing material according to claim 1 , wherein the mesothelial cells are cells derived from an individual from fetal to infant stages.5. The adhesion preventing material according to claim 1 , wherein the mesothelial cells are liver mesothelial cells.6. The adhesion preventing material according to claim 5 , which is used for adhesion prevention of a resected surface after partial hepatectomy or prevention of peritoneal adhesion.7. The adhesion preventing material according to claim 1 , wherein the mesothelial cells are peritoneal mesothelial cells.8. The adhesion preventing material according to claim 7 , which is used for prevention of peritoneal adhesion;9. The adhesion preventing material according to claim 1 , which does not comprise a support but consists only of the cell sheet.10. A method of preventing adhesion claim 1 , comprising placing a cell sheet containing mesothelial cells on the surface or resected surface of a tissue or an organ.11. A method of promoting liver regeneration claim 1 , comprising placing a cell sheet comprising liver mesothelial cells on a resected surface after partial hepatectomy.12. A method of ...

OCCLUDER INCLUDING EXTERNAL SKIRT

The present disclosure is directed to embodiments and methods of reducing or eliminating erosion resulting from the use of an occluder, as well as reducing or eliminating other interference with cardiac tissue by an occluder, including reducing pressure on cardiac tissue, minimizing micro-perforations, and/or minimizing residual leak by improving sealing around the occluder. In particular, the present disclosure is directed to providing an external skirt on an occluder that improves sealing of the occluder while reducing interference with the cardiac tissue by the occluder. 1. A medical device for treating a target site , the medical device comprising:a tubular member comprising a proximal disc portion at a proximal end and a distal disc portion at a distal end and a waist member extending between the proximal disc portion and the distal disc portion, wherein the tubular member comprises at least one braided layer and has an expanded configuration when deployed at the target site and a reduced configuration for delivery to the target site; anda skirt coupled to an external surface of at least one of the waist member, the proximal disc portion, or the distal disc portion.2. The medical device of claim 1 , wherein the skirt is coupled to the external surface of the waist member and at least one of the proximal disc portion or the distal disc portion.3. The medical device of claim 1 , wherein the skirt is coupled to the external surface of only the waist member.4. The medical device of claim 1 , wherein the skirt is coupled to the external surface of the at least one of the waist member claim 1 , the proximal disc portion claim 1 , or the distal disc portion by one or more sutures.5. The medical device of claim 1 , wherein the skirt is coupled to the external surface of the at least one of the waist member claim 1 , the proximal disc portion claim 1 , or the distal disc portion by thermal bonding.6. The medical device of claim 1 , wherein the skirt is formed from one ...

PROCESS FOR COATING A BIOMEDICAL IMPLANT WITH A BIOCOMPATIBLE POLYMER AND A BIOMEDICAL IMPLANT THEREFROM

The present invention disclosed a process to coat the surface of flexible polymeric implant with biocompatible polymer such that the coating does not crack when the implant is subjected to mechanical forces such as tension, torsion or bending while retaining the inherent properties of the coated polymer. 1. A process for obtaining an implant with a biocompatible polymer coating , said process comprising:(a) dipping the implant in a solution of biocompatible polymer to obtain an implant with a dip coating; and 'wherein, fibres of the biocompatible polymer are partially embedded into the dip coating, and said coating remains intact/independent of cracks/tears even after application of mechanical forces selected from the group consisting of bending, tensile stress, compression, and torsion.', '(b) immediately electrospinning the same polymer onto the implant with dip coating of step (a) to obtain an implant with a biocompatible polymer coating;'}2. The process as claimed in claim 1 , wherein said biocompatible polymer is selected from the group consisting of silk fibroin claim 1 , polylactic acid (PLA) claim 1 , poly ε-caprolactone (PCL) claim 1 , and collagen.3. The process as claimed in claim 2 , wherein said biocompatible polymer is silk fibroin.4. The process as claimed in claim 1 , wherein said implant is made up of a material selected from the group consisting of metal claim 1 , polymer claim 1 , ceramic claim 1 , and composites thereof.5. The process as claimed in claim 3 , wherein said metal is titanium.6. The process as claimed in claim 3 , wherein said polymer is polydimethylsiloxane (PDMS) or polyethylene.7. The process as claimed in claim 3 , wherein said ceramic is hydroxyapatite.8. The process as claimed in claim 1 , wherein said implant is selected from the group consisting of breast implant claim 1 , ocular implant claim 1 , cardiovascular stent claim 1 , and catheter tube.9. The process as claimed in claim 1 , wherein said implant is in a form selected ...

Silk Fibroin Tracheal Stent

Bioresorbable silk fibroin tracheal stents can be designed and engineered to maintain a tracheal opening. A tracheal stent will maintain a tracheal opening for a period while tissue structure and function is restored. Bioresorbable silk fibroin tracheal stents programmably degrade without negative biological or clinical outcomes. Bioresorbable silk fibroin tracheal stents do not need to be removed following tracheal restoration. Bioresorbable biopolymer tracheal stents can be internally or externally deployed. Bioresorbable biopolymer tracheal stents, for example can be internally or externally deployed in a patient. Such stents may be affixed to function as a splint with tunable mechanically properties to treat, for example, a patient with severe airway collapse. 1. A stent having a substantially cylindrical body ,wherein at least the body is comprised of a silk fibroin material characterized by beta-sheet secondary structure, andwherein the stent is designed and engineered to be grafted to an external wall of a subject's trachea.2. The stent of claim 1 , wherein the silk fibroin material present in the body is formed from a silk fibroin solution having a concentration of about 1% w/w % to about 30% w/w %.3. The stent of or claim 1 , wherein the silk fibroin material comprises an additive that is embedded within the material or coated on a surface of the body.4. The stent of claim 3 , wherein the additive is silk fibroin fibers.5. The stent of claim 3 , wherein the additive is a plasticizer.6. The stent of claim 5 , wherein the plasticizer is present in the silk fibroin material at a concentration of about 1% to about 30% by weight.7. The stent of or claim 5 , wherein the plasticizer is selected from the group consisting of: 1 claim 5 ,2-butylene glycol; 2-amino-2-methyl-1 claim 5 ,3-propanediol; 2 claim 5 ,3-butylene glycol; allyl glycolate; butyl lactate; diethanolamine; diethylene glycol monoethyl ether; ethyl glycolate; ethyl lactate; ethylene glycol; ethylene ...

Bioresorbable biopolymer stent

A bioresorbable biopolymer stents can be deployed within a blood vessel and resorbed by the body over a predetermined time period after the blood vessel has been remodeled. A ratcheting biopolymer stent can include a ratcheting mechanism that allows the biopolymer stent to be deployed on a small diameter configuration and then expanded to a predefined larger diameter configuration wherein after expansion, the ratcheting mechanism locks the biopolymer stent in the expanded configuration. A folding biopolymer stent can be deployed in a folded, small diameter configuration and then expanded to an unfolded configuration having a larger diameter. The bioresorbable biopolymer can include silk fibroin and blend that include silk fibroin materials.

APPARATUSES AND METHODS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS

The invention relates generally to the fields of biology and health sciences. More particularly, the invention relates to compositions and methods for modulating cellular physiology and pathological processing using a combination of compounds that can be found in amniotic membrane tissue and umbilical cord tissue preparations. 1. An apparatus for treating dry eye or other diseases or disorders of the eye , by insertion of the device onto the surface of the eye of a patient in need thereof , wherein the apparatus comprises: one or more flexible tubular structures , wherein the one or more flexible tubular structures comprise a material selected from the group consisting of: ethylene vinyl acetate (EVA); polydimethylsiloxane (PDMS); polymethylmetacrylate (PMMA); polyethylene teraphthalate (PET); polycarbonate (PC); hydrogels; polyvinyl chloride (PVC); rubber; latex; polyethylene (PE); silicone; polytetrafluoroethylene (PTFE); polyurethane (PU); umbilical cord tissue; amniotic membrane tissue; placental tissue; chorion tissue and any combination thereof.2. The apparatus according to claim 1 , wherein the apparatus is configured to reside in at least one of the group consisting of: superior conjunctiva fornix claim 1 , inferior conjunctiva fornix and combinations thereof.3. The apparatus according to claim 1 , wherein the apparatus is configured to reside in both conjunctiva fornices.4. The apparatus according to claim 1 , wherein the apparatus deepen the fornix tear reservoir by stretching the conjunctival sac.5. The apparatus according to claim 1 , wherein the apparatus induces blinking.6. The apparatus according to claim 1 , wherein the one or more flexible tubular structures have a length of about 0.5 cm to about 15 cm.7. The apparatus according to claim 1 , wherein the one or more flexible tubular structures have a circumference of about 2 cm to about 15 cm.8. The apparatus according to claim 7 , wherein the one or more flexible tubular structures have a ...

Methods and systems for stiffening of tissue for improved processing

Methods and systems for stiffening of tissue are presented to allow improved processing. Solutions including an acid or a base can be contacted with tissue to stiffen one or more components of the tissue. The resulting stiffened tissue can be used in the creation of wound treatment devices.

IMPLANTABLE CELL DEVICE WITH SUPPORTIVE AND RADIAL DIFFUSIVE SCAFFOLDING

The Invention features an implantable cell device that includes a membrane defining and enclosing a chamber; a distance body within the chamber for reducing the diffusion distance for a biological active factor to or across the membrane; and a support scaffold within the chamber for increasing the cell support surface area per unit volume of the chamber for distributing cells. 1. An implantable cell device comprising:a membrane defining and enclosing a chamber;a distance means, within the chamber, for reducing diffusion distance for a biologically active factor to/across the membrane; anda support means, within the chamber, for increasing cell support surface area per unit volume of the chamber for distributing cells.2. The device according to claim 1 , wherein the cells are capable of secreting a biologically active factor or providing a biological function to a recipient.3. The device according to any of the preceding claims claim 1 , wherein the biologically active factor is selected from a group consisting of neuropeptides claim 1 , neurotransmitters claim 1 , hormones claim 1 , cytokines claim 1 , lymphokines claim 1 , enzymes claim 1 , biological response modifiers claim 1 , growth factors claim 1 , antibodies and trophic factors.4. The device according to any of the preceding claims claim 1 , wherein the membrane is connected to a chamber top at one end and a chamber bottom at the other end.5. The device of claim 4 , wherein the ends comprise a plug.6. The device of claim 5 , wherein the plug comprises glue.7. The device according to any of the preceding claims claim 5 , wherein the membrane comprises at least one biocompatible semi-permeable layer across which the biologically active factor is passed through from the chamber into surroundings such as a central nervous system.8. The device according to any of the preceding claims claim 5 , wherein the membrane is made up of a material selected from a group consisting of polyacrylates including acrylic ...

Tissue repair material derived from fish skin and manufacturing method thereof

A tissue repair material derived from fish skin and manufacturing method thereof is applied to provide the tissue repair material suitable for use as a patch, a cover, a carrier, a scaffold, an implant or a reagent in various tissues. The tissue repair material has collagens to improve the wounded tissue repair, and has particular characters for desired tissue repair application. Furthermore, so far the factors of the terrestrial animal transmitted disease (caused by virus) do not survive on the tissue repair material derived from fish skin.

BIOLOGICAL MATERIAL-COATED DEVICES AND METHODS OF PRODUCING THE SAME

Biological material-coated devices and methods of producing the same. In a method to produce a coated medical device, the method comprises the steps of harvesting a tissue from a mammal, the tissue selected from the group consisting of pulmonary ligament, mediastinal pleura, parietal pleura, and visceral pleura, to obtain a harvested tissue; freezing the harvested tissue to obtain frozen tissue; mechanically processing the frozen tissue to obtain a liquid tissue product; and applying at least part of the liquid tissue product to at least part of a medical device so to at least partially coat the medical device with the liquid tissue, to produce a coated medical device. 1. A method to produce a coated medical device , the method comprising the steps of:harvesting a tissue from a mammal, the tissue selected from the group consisting of pulmonary ligament, mediastinal pleura, parietal pleura, and visceral pleura, to obtain a harvested tissue;freezing the harvested tissue to obtain frozen tissue;mechanically processing the frozen tissue to obtain a liquid tissue product; andapplying at least part of the liquid tissue product to at least part of a medical device so to at least partially coat the medical device with the liquid tissue, to produce a coated medical device.2. The method of claim 1 , wherein the tissue comprises pulmonary ligament claim 1 , and wherein the step of mechanically processing the frozen tissue is performed by blending or grinding the frozen tissue.3. The method of claim 1 , wherein the tissue comprises mediastinal pleura claim 1 , and wherein the step of mechanically processing the frozen tissue is performed by blending or grinding the frozen tissue.4. The method of claim 1 , wherein the tissue comprises parietal pleura claim 1 , and wherein the step of mechanically processing the frozen tissue is performed by blending or grinding the frozen tissue.5. The method of claim 1 , wherein the tissue comprises visceral pleura claim 1 , and wherein the ...

SINGLE CONDUIT HEART VALVE WITH UNITARY LEAFLET AND SKIRT

Embodiments herein relate to prosthetic heart valves constructed with animal tissue wherein the leaflets are unitary with the inner skirt. In an embodiment, an implantable heart valve assembly is included having a plurality of valve leaflets, an inner skirt, and a metal frame, wherein the plurality of valve leaflets and the inner skirt are formed of a continuous piece of animal tissue. In another embodiment, a method of making an implantable heart valve assembly is included, the method including placing a piece of pericardial tissue over a mold, cross-linking the pericardial tissue in place over the mold, removing the pericardial tissue from the mold, and attaching the pericardial tissue to a frame, wherein the pericardial tissue forms a seamless junction between a plurality of valve leaflets and an inner skirt. Other embodiments are also included herein. 1. An implantable heart valve assembly comprising:a plurality of valve leaflets, the plurality of valve leaflets comprising an animal tissue;an inner skirt, the inner skirt comprising an animal tissue; anda metal frame;wherein the plurality of valve leaflets and the inner skirt are formed of a continuous piece of animal tissue.2. The implantable heart valve assembly of claim 1 , wherein the animal tissue has a thickness of 100 to 500 microns.3. The implantable heart valve assembly of claim 1 , wherein the animal tissue exhibits a different degree of cross-linking in different areas of the implantable heart valve assembly.4. The implantable heart valve assembly of claim 1 , further comprising:an outer skirt, the outer skirt comprising an animal tissue.5. The implantable heart valve assembly of claim 4 , wherein the plurality of valve leaflets claim 4 , the inner skirt claim 4 , and the outer skirt are formed of a continuous piece of animal tissue.6. The implantable heart valve assembly of claim 4 , wherein the plurality of valve leaflets claim 4 , the inner skirt claim 4 , and the outer skirt are formed of a single ...

DUAL-TARGETED DRUG CARRIERS

The present invention relates to implantable medical devices containing surface-treated, dual-targeted drug carriers for treating vascular diseases. 1. An implantable medical device , comprising:a device body having an exposed surface;a drug reservoir layer disposed over at least a portion of the exposed surface of the device body;a plurality of particles embedded in the drug reservoir layer; 'the particles are surface-treated with a first substance capable of enhancing transport of the particles into a lipid-rich atherosclerotic lesion and a second substance capable of enhancing uptake of the particles into macrophages within the lesion.', 'one or more therapeutic agents encapsulated in the plurality of particles, wherein'}2. The implantable medical device of claim 1 , wherein the device is a stent.3. The implantable medical device of claim 1 , wherein the plurality of particles are selected from the group consisting of micelles claim 1 , liposomes claim 1 , polymerosomes claim 1 , hydrogel particles and polymer particles.4. The implantable medical device of claim 3 , wherein the liposome has a particle size from about 80 nm to about 1 micron.5. The implantable medical device of claim 1 , wherein the first substance is selected from the group consisting of thiolated chitosan claim 1 , TDMAC claim 1 , PPAA claim 1 , and combination thereof.6. The implantable medical device of claim 1 , wherein the second substance is selected from the group consisting of phospholipids claim 1 , DSPG claim 1 , PLA/PLGA claim 1 , ceramide claim 1 , and combination thereof.7. A method of treating a vascular disease claim 1 , comprising:deploying in the vasculature of a patient in need thereof an implantable medical device, wherein the device comprises:a device body having an exposed surface;a drug reservoir layer disposed over at least a portion of the exposed surface of the device body;a plurality of particles embedded in the drug reservoir layer; 'the particles are surface-treated ...

METHODS FOR TISSUE PASSIVATION

One aspect of the invention provides a method of preventing or reducing stenosis in a subject. The method includes implanting a passivated graft comprising vein into an artery. The implanting of the graft replaces and/or bypasses a diseased segment of the artery. The passivated graft including vein is prepared by exposing the exterior surface of the passivated graft comprising vein to a tissue structure stabilizing agent (“TSSA”) under conditions sufficient to promote cross-linking of proteins within the vein. 1. A method of preventing or reducing stenosis in a subject , the method comprising implanting a passivated graft comprising vein into an artery , wherein the implanting of the graft replaces and/or bypasses a diseased segment of the artery and wherein the passivated graft comprising vein is prepared by exposing the exterior surface of the passivated graft comprising vein to a tissue structure stabilizing agent (“TSSA”) under conditions sufficient to promote cross-linking of proteins within the vein , thereby preventing or reducing stenosis in a subject.2. The method of claim 1 , further comprising exposing the exterior surface of the implanted passivated graft comprising vein and/or the exterior surface of the artery to a tissue structure stabilizing agent (“TSSA”) under conditions sufficient to promote cross-linking of proteins within the exterior surface.3. The method of claim 2 , wherein the diseased segment of the artery contains a plaque.4. The method of claim 1 , wherein the TSSA is a photoactive agent or a chemical cross-linking compound.5. The method of claim 1 , wherein the TSSA is a photoactive agent.6. The method of claim 5 , wherein the photoactive agent is Rose Bengal (“RB”).7. The method of claim 6 , wherein the TSSA does not penetrate more than about 100 μm into connective tissue.8. The method of claim 5 , wherein the photoactive agent is selected from the group consisting of xanthenes claim 5 , flavins claim 5 , thiazines claim 5 , porphyrins ...

TISSUE REINFORCING COMPOSITIONS, DEVICES, AND METHODS OF USE

Methods for manipulating and/or reinforcing tissues are provided. The method includes applying a tissue reinforcement material to at least a portion of tissue to be manipulated and applying energy to one or both of the tissue reinforcement material and the tissue. 1. A method for treating tissue , the method comprising:applying a tissue reinforcement material to at least a portion of a tissue to be treated;applying energy to the tissue reinforcement material, the tissue, or both the tissue reinforcement material and the tissue, wherein applying energy causes fusion between at least a part of the tissue reinforcement material and at least a part of the tissue; andmanipulating the tissue.2. The method of claim 1 , wherein manipulating the tissue comprises cutting the tissue.3. The method of claim 2 , wherein fusion occurs concurrently with cutting the tissue.4. The method of claim 2 , wherein fusion commences just before a commencement of cutting the tissue.5. The method of claim 2 , wherein fusion continues until after cutting the tissue.6. The method of claim 2 , wherein fusion occurs prior to cutting the tissue.7. The method of claim 1 , wherein manipulating the tissue comprises ligation.8. The method of claim 1 , wherein manipulating the tissue is performed by a device configured to impart energy to the tissue.9. The method of claim 8 , wherein the energy comprises heat.10. The method of claim 8 , wherein the energy comprises electricity.11. The method of claim 8 , wherein the energy comprises radiation.12. The method of claim 1 , wherein applying a tissue reinforcement material to at least a portion of the tissue comprises wrapping the tissue reinforcement material around a circumference of the tissue.13. The method of claim 1 , wherein the tissue reinforcement material comprises at least one of: an oxidized cellulose claim 1 , a polyglycolic acid claim 1 , a fibrinogen claim 1 , collagen claim 1 , or a lipid.14. The method of claim 1 , wherein applying energy ...

Bioartificial pancreas

A bioartificial device, such as a bioartificial pancreas, for implantation in a patient's vascular system. The bioartificial pancreas includes a scaffold adapted to engage an interior wall of a blood vessel, a cellular complex support by the scaffold and extending longitudinally within the interior cavity of the scaffold so as to be exposed to the blood flow when the scaffold is engaged with the blood vessel, the cellular complex support comprising one or more pockets bordered by thin film; and cellular complex comprising pancreatic islets disposed in the one or more pockets, the thin film being adapted to permit oxygen and glucose to diffuse from flowing blood into the one or more pockets at a rate sufficient to support the viability of the islets. The invention also includes methods of making and using a bioartificial pancreas.

Biodegradable Mesh Implant for Soft Tissue Repair

A biodegradable mesh implant for use in soft tissue repair, in particular surgical hernia, chronic wound healing or fistula repair, within the body of a patient is disclosed. The mesh implant includes a porous, hydrophilic biodegradable polymeric carrier mesh and fibroblasts on or within the polymeric carrier mesh. The carrier mesh includes a sponge-like structure with interconnected pores of different sizes, has a water contact angle of less than 75° and is made of at least a first polymer comprising polylactic acid as a main component. 1. A biogradable mesh implant for use in soft tissue repair within the body of a patient , the mesh implant comprising:a porous, hydrophilic biodegradable polymeric carrier mesh, andfibroblasts on or within the polymeric carrier mesh,wherein the polymeric carrier mesh comprises a sponge-like structure with interconnected pores of different sizes,wherein the polymeric carrier mesh has a water contact angle of less than 75°, andwherein the polymeric carrier mesh is made of at least a first polymer comprising polylactic acid as a main component.2. The implant of claim 1 , wherein the polymeric carrier mesh has a water contact angle of less than 40°.3. The implant of claim 1 , wherein the polymeric carrier mesh has a flat claim 1 , sheet-like shape and is elastically deformable to allow folding or rolling thereof.4. The implant of claim 1 , wherein the first polymer consists of at least 70% of poly(lactic acid).5. The implant of claim 1 , wherein the polymeric carrier mesh consists of the first polymer alone or of the first polymer and at least one natural polymer selected from the group consisting of collagen claim 1 , gelatin claim 1 , laminin claim 1 , fibrinogen claim 1 , albumin claim 1 , chitin claim 1 , chitosan claim 1 , agarose claim 1 , hyaluronic acidalginatc and mixtures thereof.6. The implant of claim 5 , wherein the sponge-like structure of the polymeric carrier mesh is covered with the least one natural polymer.7. The ...

SIDE-DELIVERED TRANSCATHETER HEART VALVE REPLACEMENT

The invention relates to a transcatheter heart valve replacement (A61F2/2412), and in particular to a side delivered large diameter, low profile transcatheter prosthetic valve having a compressible tubular frame having a side wall and a central axial lumen, said tubular frame having a height of 8-20 mm and a diameter of 40-80 mm, an atrial sealing cuff, a subannular anchoring component, and aa flow control component comprising a leaflet structure, wherein the valve is side-delivered longitudinally to a mitral valve annulus or tricuspid valve annulus of a patient using a 22-34 Fr delivery catheter. 1. A side-delivered transcatheter prosthetic valve comprising:a compressible tubular frame having a side wall and a central axial lumen, said tubular frame having a height of 8-20 mm and a diameter of 40-80 mm,an atrial sealing cuff attached to a top edge of the side wall,a subannular anchoring component attached to the tubular frame, said subannular anchoring component selected from one or more of the group consisting of a lower tension arm extending from a distal side of the tubular frame, a proximal anchoring tab extending from a proximal side of the tubular frame, a ventricular sealing collar attached to a bottom edge of the side wall, and at least one tissue anchor to connect the tubular frame to native tissue, anda flow control component comprising a leaflet structure having three leaflets of pericardial material sewn to a leaflet frame to form a rounded cylinder mounted within the lumen of the tubular frame and configured to permit blood flow in a first direction through an inflow end of the valve and block blood flow in a second direction, opposite the first direction, through an outflow end of the valve,wherein the valve is compressible to a compressed configuration for introduction into the body using a delivery catheter for implanting at a mitral valve annulus or tricuspid valve annulus of a patient, said delivery catheter having an internal diameter from 22 Fr ...

3D PRINTED POLYVINYL ALCOHOL MEDICAL DEVICES AND METHODS OF ACTIVATION

A medical device comprising a structure formed of polyvinyl alcohol. 1. A medical device comprising:a structure formed of polyvinyl alcohol.2. The medical device of wherein the polyvinyl alcohol is cross-linked.3. The medical device of wherein the polyvinyl alcohol is cross-linked by a reaction including an aldehyde.4. The medical device of wherein the aldehyde is glutaraldehyde.5. The medical device of wherein a medically functional chemical is loaded onto the structure.6. The medical device of wherein the medically functional chemical is iodine.7. The medical device of wherein the medically functional chemical is one of Bromine claim 6 , a divalent cation claim 6 , a protein claim 6 , an antibiotic claim 6 , and an anti-cancer drug claim 6 , a therapeutic claim 6 , a regulatory molecule claim 6 , a matrix molecule claim 6 , a guidance molecule claim 6 , a growth factor claim 6 , collagen claim 6 , a stem cell matrix claim 6 , a smooth muscle cell matrix claim 6 , and a cell.8. The medical device of wherein the medically functional chemical is one of Zinc claim 7 , Copper claim 7 , and Iron II.9. The medical device of wherein the medical device is one of a vascular stent claim 1 , a product for use in a non-vascular anatomical space claim 1 , a wound care product claim 1 , a wound dressing claim 1 , an antimicrobial surface claim 1 , a vascular access graft claim 1 , a coronary artery bypass grafts claim 1 , a skin replacement claim 1 , a duct replacement claim 1 , a bone replacement claim 1 , and a vascular conduit.10. A method for creating a medical device comprising:3D printing the medical device out of polyvinyl alcohol.11. The method of further comprising the step of crosslinking the polyvinyl alcohol with an aldehyde.12. The method of wherein the crosslinking of the polyvinyl alcohol with the aldehyde is facilitated with an acid.13. The method of wherein the acid is HCI.14. The method of wherein the crosslinking of the polyvinyl alcohol with the aldehyde is ...

POROUS ORTHOPEDIC MATERIALS COATED WITH DEMINERALIZED BONE MATRIX

A biomaterial including a porous biocompatible structure having interconnected pores, wherein the pores have interior walls and are interconnected by passageways, the interior walls and passageways being coated with an osteoinductive aqueous demineralized bone extract solution, the aqueous demineralized bone extract solution including growth factors, proteins, a demineralized bone matrix and at least one of a weak acid and a guanidine hydrochloride, wherein the demineralized bone matrix is present per 100 g of the solution in an amount of from about 2 g to about 10 g. 1a porous biocompatible structure comprising interconnected pores, wherein the pores comprise interior walls and are interconnected by passageways;an aqueous demineralized bone extract coating comprising growth factors, proteins or a combination thereof; anda demineralized bone gelatin coating comprising a demineralized bone matrix gelatin;wherein the demineralized hone extract coating and the demineralized bone gelatin coating cover the interior walls and passageways.. A biomaterial comprising: This application is a continuation of U.S. patent application Ser. No. 11/688,912 filed Mar. 21, 2007, and entitled “Porous Orthopedic Materials Coated with Demineralized Bone Matrix,” the disclosure of which is expressly incorporated in its entirety herein by this reference.This invention relates generally to coated porous orthopedic materials and more specifically to porous orthopedic materials coated with demineralized bone matrix extracts comprising growth factors.Prosthetic devices and bone implants can either be made of resorbable or non-resorbable materials. In particular, current bone graft materials include autografts (bone material obtained from the patient), allografts (cadaver bone and bone material typically obtained from tissue banks); xenografts (bone materials from animals), and a variety of artificial or synthetic bone substitute materials. Such bone substitute materials include materials that ...

Embolization Device Constructed From Expansile Polymer

Devices for the occlusion of body cavities, such as the embolization of vascular aneurysms and the like, and methods for making and using such devices. The devices may be comprised of novel expansile materials, novel infrastructure design, or both. The devices provided are very flexible and enable deployment with reduced or no damage to bodily tissues, conduits, cavities, etceteras. 120.-. (canceled)21. An occlusion device comprising:an elongated, solid expansile element, that is flexible in an untreated state, consisting essentially of a poly(ethylene glycol) macromer and a pH sensitive monomer; anda carrier element comprising a plurality of loops forming a helical shape disposed around the expansile element,wherein the plurality of loops are spaced at least one gap and the gap is between about 0.00025 inches and about 0.2 inches.22. The occlusion device of claim 21 , wherein the carrier element is between about 0.005 inches and about 0.035 inches in diameter.23. The occlusion device of claim 21 , wherein the carrier element is between about 0.0005 inches and about 0.01 inches in diameter.24. The occlusion device of claim 21 , wherein the carrier element is between about 0.008 inches and about 0.016 inches in diameter.25. The occlusion device of claim 21 , wherein the carrier element is between about 0.00075 inches and about 0.004 inches in diameter.26. The occlusion device of claim 21 , wherein the elongated claim 21 , solid claim 21 , flexible expansile element is between about 0.001 inches and about 0.03 inches in diameter before expansion.27. The occlusion device of claim 21 , wherein the elongated claim 21 , solid claim 21 , flexible expansile element is between about 0.002 inches and about 0.25 inches in diameter after expansion.28. The occlusion device of claim 21 , wherein the pH sensitive monomer is sodium acrylate.29. The occlusion device of claim 21 , wherein the elongated claim 21 , solid claim 21 , flexible expansile element is secured to the carrier ...

Cell bandage

The invention provides a method for delivering cells across the surface of a tissue, the method comprising distributing the cells on and/or within a biomaterial to form a cell bandage and applying the cell bandage to the surface, wherein, after application of the cell bandage to the surface of the tissue, the cells are released from the cell bandage. Further provided is a method for bonding two or more tissues, the method comprising providing a cell bandage in intimate contact with the surfaces to be joined, wherein the cell bandage comprises a biomaterial, said biomaterial having cells distributed on and/or within it.

Synergistic Compositions for Gynecological Procedures

Synergistic compositions for use in treatment during gynecological procedures are provided. Synergistic compositions that enable practitioners to perform gynecological procedures without pain or bleeding to patients are provided. 1. A synergistic combination comprising a neuroanalgesic and a prostaglandin for reducing or eliminating pain and bleeding during invasive gynecological procedures.2. The synergistic combination of claim 1 , wherein the neuroanalgesic is fentanyl and the prostaglandin is misoprostol.3. The synergistic combination of claim 2 , wherein a dose of the synergistic combination comprises the fentanyl in an amount ranging from about 15 μg to about 20 μg and comprises the misoprostol in an amount ranging from about 75 μg to about 175 μg.4. The synergistic combination of claim 1 , wherein the synergistic combination further comprises a component selected from the group consisting of an analgesic claim 1 , an anesthetic claim 1 , a spasmolytic claim 1 , a muscle relaxant claim 1 , and combinations thereof.5. The synergistic combination of claim 4 , wherein the analgesic is selected from the group consisting of acetaminophen claim 4 , ibuprofen claim 4 , morphine claim 4 , naproxen claim 4 , oxycodone claim 4 , and combinations thereof.6. The synergistic combination of claim 4 , wherein the anesthetic is selected from the group consisting of lidocaine claim 4 , prilocaine claim 4 , tetracaine claim 4 , iontocaine claim 4 , and combinations thereof.7. The synergistic combination of claim 4 , wherein the spasmolytic is selected from the group consisting of hyoscine claim 4 , carisoprodol claim 4 , cyclobenzaprine claim 4 , metaxalone claim 4 , methocarbamol claim 4 , and combinations thereof.8. The synergistic combination of claim 4 , wherein the muscle relaxant is selected from the group consisting of thiocolchicoside claim 4 , meprobamate claim 4 , barbiturates claim 4 , methaqualone claim 4 , glutethimide claim 4 , ketobemidone claim 4 , piritramide.9 ...

TISSUE FIBROSIS INHIBITOR IN WHICH BIOCOMPATIBLE POLYMER IS USED

A problem to be solved by the present invention is to provide a fibrosis inhibitor that solves the problem of inhibiting fibrosis of an organ or tissue surface, and especially of inhibiting fibrosis of an epicardial surface. Furthermore, by inhibiting fibrosis, the present invention prevents or reduces subsequent development of adhesions to avoid organ or tissue damage during re-operation. Provided is a fibrosis inhibitor for inhibiting fibrosis of a tissue by fixing a biocompatible polymer to a tissue where it is desirable to inhibit fibrosis. 1. A tissue fibrosis inhibitor comprising a biocompatible polymer.2. The fibrosis inhibitor according to claim 1 , wherein the biocompatible polymer is fibrin or a dextrin gel.3. A tissue fibrosis inhibition kit comprising a combination of a biocompatible polymer and a cell scaffold material.4. The fibrosis inhibition kit according to claim 3 , wherein the biocompatible polymer is fixed to one tissue fibrosis of which is to be inhibited claim 3 , and prosthesis is made with the cell scaffold material for a tissue defect site in the other tissue.5. The fibrosis inhibition kit according to claim 3 , wherein the biocompatible polymer is fibrin or a dextrin gel.6. The fibrosis inhibition kit according to claim 3 , wherein the cell scaffold material is a decellularized tissue.7. The fibrosis inhibition kit according to claim 6 , wherein the decellularized tissue is a tissue produced by decellularizing a biological tissue selected from the group consisting of a small intestinal submucosa claim 6 , pericardium claim 6 , bladder claim 6 , amnion claim 6 , dura mater claim 6 , peritoneum claim 6 , greater omentum claim 6 , thoracic diaphragm claim 6 , fascia claim 6 , dermis and skin.8. The fibrosis inhibition kit according to claim 3 , which promotes the self-organization of the cell scaffold material.9. The fibrosis inhibition kit according to claim 3 , wherein the tissue fibrosis of which is to be inhibited is epicardium.10. A ...

Extracellular matrix sheet structures

An implantable medical product and method of use for substantially reducing or eliminating harsh biological responses associated with conventionally implanted medical devices, including inflammation, infection and thrombogenesis, when implanted in in a body of a warm blooded mammal. The bioremodelable pouch structure is configured and sized to receive, encase and retain an electrical medical device therein and to allow such device to be inserted into the internal region or cavity of the pouch structure; with the pouch structure formed from either: (a) first and second sheets, or (b) a single sheet having first and second sheet portions. After receiving the electrical device, the edges around the opening are closed by suturing or stapling. The medical device encased by the bioremodelable pouch structure effectively improves biological functions by promoting tissue regeneration, modulated healing of adjacent tissue or growth of new tissue when implanted in the body of the mammal.

BIOSORBABLE ENDOPROSTHESIS

A biosorbable magnetisable endoprosthesis, may be useful in the therapy of restenosis. A method for the treatment of prevention of restenosis or a disease of the coronary artery, comprises fitting a patent with an endoprosthesis according to the invention, which has either been magnetized prior to placement in the body or which is magnetized in situ, and administering to the patient magnetized cells capable of repairing an artery. 1. A biosorbable magnetisable endoprosthesis.2. An endoprosthesis according to claim 1 , which is a stent.3. An endoprosthesis according to claim 1 , wherein a portion of the endoprosthesis can be absorbed by the body claim 1 , such that structural integrity of the stent is lost between 6 and 12 months after placement in the body.4. An endoprosthesis according to claim 1 , comprising magnetic particles within a biosorbable material.5. An endoprosthesis claim 1 , which is made from a material which is both biosorbable and magnetisable.6. An endoprosthesis according to claim 4 , wherein the magnetic particles comprise iron.7. An endoprosthesis according to claim 1 , wherein the biosorbable material comprises magnesium or iron claim 1 , or an alloy thereof.8. An endoprosthesis according to claim 1 , wherein the biosorbable material comprises a biosorbable polymer.9. A kit comprising a magnetisable endoprosthesis and magnetisable cells capable of repairing an artery.10. A kit according to claim 9 , wherein the cells are progenitor cells claim 9 , preferably endothelial progenitor cells.11. A kit according to claim 9 , wherein the cells comprise iron.12. A kit according to claim 9 , as a combined preparation for simultaneous claim 9 , separate or sequential use in therapy.1317-. (canceled)18. A method for the treatment or prevention of restenosis claim 1 , stent thrombosis or a disease of a blood vessel claim 1 , comprising (a) fitting a patent with an endoprosthesis according to claim 1 , which has either been magnetized prior to placement in ...

Tissue Repair Implant

Described herein are tissue repair implants comprising at least a first layer of peritoneal membrane. The first layer of peritoneal membrane can be located adjacent to a second layer of peritoneal membrane and can be in direct contact with the second layer of peritoneal membrane. Additional layers (e.g., a third or fourth layer) can be included. Where more than one layer is present, the layers can be affixed to one another. For example, a first layer of peritoneal membrane can be attached to the second layer of peritoneal membrane by an adhesive bond, suture, or staple. One or more of the peritoneal membranes can be non-crosslinked, partially crosslinked, or substantially fully crosslinked. Any of the layers of peritoneal membrane may be attached to a wall (e.g., an interior or exterior wall) of an abdominal tissue by an adhesive, suture, and/or staples. 1. A tissue repair implant comprising a first layer of peritoneal membrane and a second layer of peritoneal membrane.2. The implant of claim 1 , wherein the first layer of peritoneal membrane is located adjacent to the second layer of peritoneal membrane.3. The implant of claim 1 , wherein the first layer of peritoneal membrane is in direct contact with the second layer of peritoneal membrane.4. The implant of claim 1 , wherein at least one of the layers of peritoneal membrane is non-crosslinked.5. The implant of claim 1 , wherein at least one of the layers of peritoneal membrane is partially crosslinked.6. The implant of claim 1 , wherein at least one of the layers of peritoneal membrane is substantially fully crosslinked.7. The implant of claim 1 , wherein the first layer of peritoneal membrane and/or the second layer of peritoneal membrane is configured to be remodeled by in-growth of tissue.8. The implant of claim 7 , wherein the first layer of peritoneal membrane and/or the second layer of peritoneal membrane is configured to promote in-growth of tissue.9. The implant of claim 1 , wherein the first layer of ...

BIOACTIVE IMPLANTS AND METHODS OF MAKING AND USING

The present application relates to bioactive implants, methods of making bioactive implants, and methods of using bioactive implants to treat or repair a bone defect or a cartilage defect. In an aspect, the present application relates to compositions comprising bone microparticles in a solution, wherein the compositions harden upon desiccation into bioactive implants. In an aspect, the present application relates to compositions comprising cartilage microparticles in a solution, wherein the compositions harden upon desiccation into bioactive implants. In an aspect, disclosed herein are methods of making and using the disclosed compositions comprising bone microparticles and the disclosed composition comprising cartilage microparticles. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention. 1. A composition , comprising: bone microparticles in a solution , wherein the bone microparticles comprise partially decalcified bone microparticles , wherein the size of the bone microparticles is from about 20 μm to about 800 μm , and wherein the composition hardens upon desiccation into a bioactive implant.2. The composition of claim 1 , wherein the hardened bioactive implant has a predetermined size and shape.3. The composition of claim 1 , wherein the solution comprises hydroxyethyl starch.4. The composition of claim 1 , wherein the solution comprises polyvinyl pyrrolidone claim 1 , povidone iodine claim 1 , collagen claim 1 , or albumin.5. The composition of claim 1 , wherein the composition comprises about 25% w/v of bone microparticles.6. The composition of claim 1 , wherein the solution comprises a solvent and wherein the solvent comprises water claim 1 , saline claim 1 , or a balanced salt solution.7. The composition of claim 1 , comprising: an agent claim 1 , wherein the agent comprises one or more of a therapeutic agent claim 1 , a bone morphogenetic protein claim 1 , an ...

ANASTOMOTIC/OCCLUSION REINFORCING AND REPAIRING COMPOSITE MEMBER AS WELL AS PREPARATION AND APPLICATION METHOD THEREOF

The present disclosure relates to the technical field of medical equipment and discloses an anastomotic/occlusion reinforcing and repairing composite member which includes a reinforcing and repairing portion, a protection portion and a connecting thread, wherein two ends of the reinforcing and repairing portion are detachably connected by the connecting thread; and the protection portion penetrates into a space enclosed by the two ends of the reinforcing and repairing portion. The present disclosure also provides a preparation and application method of the anastomotic/occlusion reinforcing and repairing composite member. 1. An anastomotic/occlusion reinforcing and repairing composite member , wherein the anastomotic/occlusion reinforcing and repairing composite member comprises a reinforcing and repairing portion , a connecting thread which detachably connects two ends of the reinforcing and repairing portion , and a protection portion which penetrates into a space enclosed by the two ends of the reinforcing and repairing portion.2. The anastomotic/occlusion reinforcing and repairing composite member according to claim 1 , wherein a material of the reinforcing and repairing portion is non-immunogenic and degradable in vivo; a material of the protection portion is one of a synthetic polymer material claim 1 , ceramic material claim 1 , metal material claim 1 , Tyvek paper claim 1 , and medical synthetic paper claim 1 , or a combination of some of them; and a material of the connecting thread is a medically usable thread.3. The anastomotic/occlusion reinforcing and repairing composite member according to claim 1 , wherein the protection portion is a planar sheet or a curved sheet claim 1 , a thickness of the protection portion is 50 to 10000 μm claim 1 , and a length of the protection portion is greater than the length of the reinforcing and repairing portion.4. The anastomotic/occlusion reinforcing and repairing composite member according to claim 1 , wherein the ...

Compliance control stitching in substrate materials

Compliance control stitch patterns sewn or embroidered into biotextile or medical textile substrates impart reinforcing strength, and stretch resistance and control into such substrates. Compliance control stitch patterns may be customizable to particular patients, substrate implantation sites, particular degenerative or diseased conditions, or desired time frames. Substrates having compliance control stitch patterns sewn or embroidered into them may be used in tissue repair or tissue reconstruction applications.

Implantable Device for Implantation of Cells Having Anti-Inflammatory and Vascularization Capabilities and Methods of Making Thereof

A method includes spreading a solution including a polyether and a photoinitiator onto a hydrophilic porous membrane, impregnating hydrophilic the porous membrane with the solution, and curing the solution located within the hydrophilic porous membrane by exposure to ultraviolet light to produce a composite membrane. 1. A method , comprising:spreading a solution on a hydrophilic porous membrane, the solution including a polyether and a photoinitiator;impregnating the hydrophilic porous membrane with the solution; andcuring the solution located within the hydrophilic porous membrane by exposure to ultraviolet light to produce a composite membrane.2. The method of claim 1 , wherein the composite membrane has a suitable pore size such that molecules having a molecular weight of greater than about 100 claim 1 ,000 Daltons are prevented from passing through the membrane.3. The method of claim 1 , further comprising:drying the composite membrane by either oven-drying or lyophilizing.4. The method of claim 3 , further comprising:placing the dried composite membrane in an implantable device.5. The method of claim 4 , further comprising: mixing functional cells with a polymer to produce a cell mixture;', 'placing the cell mixture on the composite membrane; and', 'cross-linking the cell mixture with a cross-linking agent to produce an embedded cell layer adjacent the composite membrane,, 'prior to the step of placing the dried composite membrane in the implantable device, performing the steps ofwherein, when the dried composite membrane is placed in the implantable device, the embedded cell layer is also placed in the implantable device.6. The method of claim 5 , wherein the cross-linking agent includes at least one of barium claim 5 , strontium claim 5 , and calcium.7. The method of claim 5 , wherein the functional cells include at least one of islets of Langerhans claim 5 , stem cells claim 5 , and adrenal cells.8. The method of claim 5 , wherein the implantable device is ...

Devices and methods for protecting against neuromas

The subject invention provides devices and methods for alleviating discomfort associated with neuroma formation. The devices and methods of the invention effectively use the body's natural response of reconstructing implanted biomaterials to minimize the size of isolate, and protect a neuroma. In preferred embodiments, the subject device is a cylindrical cap, wherein the internal chamber of the cylindrical cap physically partitions the nerve to enable an arrangement of nerve fibers (as opposed to haphazardly arranged nerve fibers often produced in neuromas). Tabs arranged on the outside of the cap can be used to manipulate the cap into place on a nerve. The open end can also be configured with flaps that can be used to widen the open end for easier insertion of the nerve into the cap. In addition, the cap's material remodels into a tissue cushion after implantation, which protects the neuroma from being stimulated and inducing pain.

STENTS MODIFIED WITH MATERIAL COMPRISING AMNION TISSUE AND CORRESPONDING PROCESSES

A stent scaffold combined with amniotic tissue provides for a biocompatible stent that has improved biocompatibility and hemocompatibility. The amnion tissue can be variously modified or unmodified form of amnion tissue such as non-cryo amnion tissue, solubilized amnion tissue, amnion tissue fabric, chemically modified amnion tissue, amnion tissue treated with radiation, amnion tissue treated with heat, or a combination thereof. Materials such as polymer, placental tissue, pericardium tissue, small intestine submucosa can be used in combination with the amnion tissue. The amnion tissue can be attached to the inside, the outside, both inside and outside, or complete encapsulation of the stent scaffold. In some embodiments, at least part of the covering or lining comprises a plurality of layers of amnion tissue. The method of making the biocompatible stent and its delivery and deployment are also discussed.

TISSUE-SEPARATING FATTY ACID ADHESION BARRIER

Exemplary embodiments of the present invention provide adhesion barriers having anti-adhesion and tissue fixating properties. The adhesion barriers are formed of fatty acid based films. The fatty acid-based films may be formed from fatty acid-derived biomaterials. The films may be coated with, or may include, tissue fixating materials to create the adhesion barrier. The adhesion barriers are well tolerated by the body, have anti-inflammation properties, fixate, well to tissue, and have a residence time sufficient to prevent post-surgical adhesions. 149-. (canceled)50. A coated medical device comprising:a medical device structure; andan anti-adhesion material covering at least a portion of the medical device structure, wherein the anti-adhesion material has tissue anti-adhesion characteristics, wherein the anti-adhesion material comprises omega-3 fatty acids cross-linked directly to each other, wherein the cross-links include ester bonds, wherein the anti-adhesion material is bioabsorbable; andwherein the coated medical device is implantable in tissue and persists, in vivo, for a duration of at least days to months.51. The coated medical device of claim 50 , wherein the omega-3 fatty acids of the anti-adhesion material comprise one or more fish oil omega-3 fatty acids.52. The coated medical device of claim 50 , wherein the anti-adhesion material is the product of cross-linking an oil composition that includes eicosapentaenoic acid claim 50 , docosahexanoic acid and alpha-linolenic acid.53. The coated medical device of claim 52 , wherein the oil composition is obtained from fish oil.54. The coated medical device of claim 50 , wherein the medical device structure induces inflammation when implanted in a patient and the anti-adhesion material reduces the inflammation otherwise associated with the medical device structure.55. The coated medical device of claim 50 , wherein the anti-adhesion material is formulated as an emulsion of cured fish oil particles dispersed in ...

Coated Surgical Mesh, and Corresponding Systems and Methods

Disclosed herein are medical products, including a surgical mesh, with a layer of dehydrated modified basement membrane preparation formed thereon. The basement membrane has been modified before dehydration of remove low molecular weight components. In some embodiments, the basement membrane is crosslinked. Methods of making and using the products also are disclosed. 1. A surgical mesh with a layer of dehydrated modified basement membrane preparation formed thereon.2. The surgical mesh of claim 1 , wherein the modified basement membrane preparation is dehydrated when in the form of a gel at room temperature.3. The surgical mesh of claim 1 , wherein the modified basement membrane preparation is dehydrated at a temperature in the range of 1-4 Dec. C after being placed on the sensor tip when the basement membrane is in the form of a liquid.4. The surgical mesh of claim 1 , wherein the modified basement membrane preparation is dehydrated at a temperature in the range of 10-30 Dec. C.5. The surgical mesh of claim 1 , wherein the modified basement membrane preparation is applied in multiple layers claim 1 , and the modified basement membrane preparation is dehydrated after application of each layer.6. The surgical mesh of claim 1 , wherein the mesh also comprises layers of other extracellular matrices formed thereon.7. The surgical mesh of claim 1 , wherein the modified basement membrane preparation contains cells and/or factors.8. A kit comprising the surgical mesh of enclosed in sterile packaging.9. A method comprising:obtaining a basement membrane preparation containing basement membrane and at least one member selected from the group consisting of salts, glucose, individual amino acids, and vitamins,removing at least a portion of at least one of the salts, glucose, individual amino acids and vitamins from the basement membrane to form a modified basement membrane preparation,obtaining an implantable device comprising a surgical mesh,placing the modified basement ...

POLYMER FILM AND POLYMERIC BAG FOR HOLDING A MEDICAL-TECHNICAL PRODUCT TO BE IMPLANTED

The polymer film serves for the embedding of a medical technology product to be implanted in a human organism. The polymer film includes a polymer of natural origin being biodegradable and absorbable by the human body. The polymer film has a polymer content. The polymer film further includes two antimicrobial active ingredients having a different mechanism of action and the polymer film has a total active-ingredient content. The ratio of the total active-ingredient content to the polymer content is at least 15%. The polymer content is greater than the total active-ingredient content. The polymer film is bendable and modulable and uninterrupted. The polymer forms a polymer matrix in which the antimicrobial active ingredients are embedded in a homogeneously distributed manner. The polymer film has, for each of the antimicrobial active ingredients, an individual active-ingredient content deviating from one another by at most 20%. 1. A polymer film for the embedding of a medical technology product to be implanted in a human organism , whereina) the polymer film comprises, as main constituent, a polymer of natural origin that is biodegradable and is absorbable by the human body and the polymer film has a polymer content,b) the polymer film comprises, as further constituents, at least two antimicrobial active ingredients having a different mechanism of action in each case and the polymer film has a total active-ingredient content,c) wherein the ratio of the total active-ingredient content to the polymer content is at least 15%, but the polymer content is greater than the total active-ingredient content,d) the polymer film is bendable and modulable, so that the polymer film can be applied closely on the medical technology product, wherein the polymer film at least mostly matches itself to the contours of the medical technology product,e) the polymer film is uninterrupted,f) the polymer forms a polymer matrix in which the at least two antimicrobial active ingredients are ...

COATINGS FORMED FROM STIMULUS-SENSITIVE MATERIAL

A coating comprising a stimulus-responsive material and a bioactive agent for controlled release of the bioactive agent and methods of making and using the same are disclosed. 1. An implantable medical device comprising a coating that comprises a stimulus-responsive material and at least one bioactive agent;wherein the bioactive agent comprises a layer of endothelial cells.2. The implantable medical device of wherein the stimulus-responsive material is a material that upon exposure to a stimulus undergoes a change of at least one physical or chemical property such that the release rate of the bioactive agent changes.3. The implantable medical device of wherein the coating comprises at least one other bioactive agent claim 1 , the other bioactive agent being an antiproliferative claim 1 , antiinflammatory claim 1 , immune-modulating claim 1 , antimigratory claim 1 , antineoplastic claim 1 , antimitotic claim 1 , antiplatelet claim 1 , anticoagulant claim 1 , antifibrin claim 1 , antibiotic claim 1 , antioxidant claim 1 , antiallergic claim 1 , or antithrombotic claim 1 , or a pro-healing agent claim 1 , or a combination of these.4. The implantable medical device of wherein the coating comprises at least one other bioactive agent claim 1 , the other bioactive agent being selected from the group consisting of paclitaxel claim 1 , docetaxel claim 1 , estradiol claim 1 , 17-beta-estradiol claim 1 , nitric oxide donors claim 1 , super oxide dismutases claim 1 , super oxide dismutases mimics claim 1 , 4-amino-2 claim 1 ,2 claim 1 ,6 claim 1 ,6-tetramethylpiperidine-1-oxyl (4-amino-TEMPO) claim 1 , tacrolimus claim 1 , dexamethasone claim 1 , rapamycin claim 1 , rapamycin derivatives claim 1 , 40-O-(2-hydroxy)ethyl-rapamycin (everolimus) claim 1 , 40-O-(3-hydroxy)propyl-rapamycin claim 1 , 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin claim 1 , 40-O-tetrazole-rapamycin claim 1 , 40-epi-(N1-tetrazolyl)-rapamycin (ABT-578) claim 1 , γ-hiridun claim 1 , clobetasol claim 1 , ...

Biodegradable supporting device

A biodegradable in vivo supporting device is disclosed. The in vivo supporting device comprises a biodegradable metal scaffold and a biodegradable polymer coating covering at least a portion of the biodegradable metal scaffold, wherein the biodegradable polymer coating has a degradation rate that is faster than the degradation rate of the biodegradable metal scaffold.

Drug coating layer

A drug coating layer on a non-porous nylon elastomer balloon substrate surface comprising a plurality of elongated bodies with long axes wherein each elongated body is formed of a crystal of a water-insoluble drug and is independently formed on the substrate surface, wherein the long axes of the elongated bodies are substantially linear in shape, and the long axes of the elongated bodies form an angle in a predetermined range with respect to a substrate plane with which the long axis of the elongated body intersects. The drug coating layer can provide low toxicity and a high intravascular stenosis inhibitory effect.

QUILTED IMPLANTABLE GRAFT

Described are embodiments of a multilaminate or multiple layer implantable surgical graft with an illustrative graft comprising a remodelable collagenous sheet material, the graft including one or more interweaving members to stitch together the graft to help prevent the layers from delaminating or separating during handling and the initial stages of remodeling. The interweaving members may comprise lines of suture, thread, individual stitches, strips of material, etc. that are woven through the layers of biomaterial in a desired pattern. In one embodiment, the interweaving members comprise a pharmacologically active substance, such as a drug, growth factors, etc. to elicit a desired biological response in the host tissue. In another embodiment, the graft further comprises a reinforcing material, such as a synthetic mesh, within the layers of remodelable biomaterial and stitched together by one or more interweaving members. 1. A multilayer surgical graft , comprising:a first remodelable extracellular matrix sheet;a second remodelable extracellular matrix sheet;a synthetic mesh material disposed between said first remodelable extracellular matrix sheet and said second remodelable extracellular matrix sheet; andat least one interweaving member interwoven through said first remodelable extracellular matrix sheet and said second remodelable extracellular matrix sheet such that said first remodelable extracellular matrix sheet and said second remodelable extracellular matrix sheet are affixed together.2. The multilayer surgical graft of claim 1 , wherein said first remodelable extracellular matrix sheet includes two or more laminated remodelable extracellular matrix layers.3. The multilayer surgical graft of claim 2 , wherein said second remodelable extracellular matrix sheet includes two or more laminated remodelable extracellular matrix layers.4. The multilayer surgical graft of claim 3 , wherein said at least one interweaving member comprises a bioresorbable material. ...

Gait Helper

A gait helper includes an hallow tubular member that is designed to elastically fit on the toenails of an animal to treat or prevent a medical condition such as, for example, lupoid onychodystrophy, moist eczema, arthritis or other joint problems. 1. A tubular gait helper comprising a hallow tubular member having an internal surface , an outer surface , a proximal end and a distal end , wherein the hallow tubular member has a portion at or near the distal end , which is thicker than the thickness of the hallow tubular member at the proximal end , wherein said hallow tubular member is adopted to elastically fit on a nail of a dog so that said hallow tubular member remains on the nail without any holding devices while the dog is walking.2. The tubular gait helper according to claim 1 , said thicker portion of said hallow tubular member covers less than 50% of the perimeter of said hallow tubular member.3. The tubular gait helper according to claim 1 , said thicker portion of said hallow tubular member has a shoe surface claim 1 , wherein the shoe surface has one or more grooves providing uneven surface.4. The tubular gait helper according to claim 1 , said internal surface has one or more reservoirs capable of holding one or drugs to be delivered to said nail.5. The tubular gait helper according to claim 1 , further comprising a second hallow tubular member adopted to elastically fit on a nail of a dog claim 1 , wherein said hallow tubular member and said second hallow tubular member are connected by a bridge providing a predetermined distance between the two hallow tubular member.6. The tubular gait helper according to claim 5 , the bridge is made of an elastic material and capable of maintain a minimum length.7. The tubular gait helper according to claim 5 , the bridge is detachable.8. The tubular gait helper according to claim 1 , wherein the thicker portion has an angled portion toward the distal end.9. The tubular gait helper according to claim 8 , wherein the ...

EMBOLIZATION DEVICE CONSTRUCTED FROM EXPANSILE POLYMER

Devices for the occlusion of body cavities, such as the embolization of vascular aneurysms and the like, and methods for making and using such devices. The devices may be comprised of novel expansile materials, novel infrastructure design, or both. The devices provided are very flexible and enable deployment with reduced or no damage to bodily tissues, conduits, cavities, etceteras. 1. A device for implantation in an animal comprising:an expansile hydrogel having ionizable functional groups formed from a solution including a monomer and a macromer, anda carrier member configured to coaxially house the expansile hydrogel.2. The device of claim 1 , wherein the expansile hydrogel has an unexpanded bending resistance of about 0.1 mg to about 85 mg.3. The device of claim 1 , wherein the macromer has a molecular weight of about 400 grams/mole to about 35 claim 1 ,000 grams/mole.4. The device of claim 1 , wherein the macromer includes polyethers claim 1 , polyurethanes claim 1 , derivatives thereof claim 1 , or combinations thereof.5. The device of claim 1 , wherein the ionizable functional groups comprise basic groups.6. The device of claim 5 , wherein the basic groups comprise an amine claim 5 , derivatives thereof claim 5 , or combinations thereof.7. The device of claim 6 , wherein the basic functional groups are deprotonated at pHs greater than the pKa or protonated at pHs less than the pKa of the functional groups.8. The device of claim 1 , wherein the ionizable functional groups comprise acidic groups.9. The device of claim 8 , wherein the acidic groups comprise a carboxylic acid claim 8 , derivatives thereof claim 8 , or combinations thereof.10. The device of claim 9 , wherein the acidic functional groups are protonated at pHs less than the pKa or de-protonated at pHs greater than the pKa of the functional groups.11. The device of claim 1 , wherein the monomer includes vinyl claim 1 , acrylates claim 1 , acrylamides claim 1 , methacrylates claim 1 , derivatives ...

METHOD OF ISOLATING CELLS FOR THERAPY AND PROPHYLAXIS

Disclosed are methods for isolating endothelial progenitor cells (EPC). More particularly, the present invention discloses methods for isolating endothelial progenitor cells that exhibit self-renewal and differentiation capacity. The isolated cellular population of the present invention is useful in a wide range of clinical and research setting including inter alia, the in vitro or in vivo generation of endothelial cells and the therapeutic or prophylactic treatment of a range of conditions via the administration of these cells. Also facilitated is the isolation of endothelial progenitor cells for research purposes such as in vitro based screening systems for testing the therapeutic impact and/or toxicity of potential treatment or culture regimes to which these cells may be exposed to. The present invention also discloses methods for isolating mesenchymal stem cells, in particular mesenchymal stem cells of fetal and/or maternal origin. These cells are also useful in a range of in vitro and in vivo therapeutic, prophylactic and research applications. 152.-. (canceled)53. A method of isolating mammalian mesenchymal stem cells (MSC) said method comprising the steps of:(i) isolating a mammalian cellular population;{'sup': '−', 'claim-text': [{'sup': −', '+', '+', '−, '(a) enriching for a subpopulation of the CD45 cells derived from step (ii) which express a CD34 phenotypic profile and isolating the subpopulation of said CD34 cells which express a CD31 phenotypic profile and/or'}, {'sup': −', '−, '(b) isolating the subpopulation of CD45 cells derived from step (ii) which express a CD34 phenotypic profile, to thereby isolate the mesenchymal stem cells.'}], '(ii) enriching for a subpopulation of the cells of step (i), which subpopulation expresses a CD45 phenotypic profile; and'}54. A method according claim 53 , wherein the CD3 population is a fetal CD3 population and said mesenchymal stem cells are fetal mesenchymal stem cells.55. A method according to claim 53 , wherein ...

METHODS FOR INCREASING A RETENTION FORCE BETWEEN A POLYMERIC SCAFFOLD AND A DELIVERY BALLOON

A medical device includes a scaffold crimped to a catheter having an expansion balloon. The scaffold is crimped to the balloon by a process that includes inflating the delivery balloon during a diameter reduction to improve scaffold retention and maintaining an inflated balloon during the diameter reduction and prior and subsequent dwell periods. 1. A method for crimping a polymer scaffold to a balloon , comprising:(a) reducing a scaffold diameter from an initial diameter to a final diameter; and(b) interrupting the reducing the scaffold diameter from the initial diameter to the final diameter by performing at least two dwell breaks during which the scaffold diameter is held constant for a dwell period of time, wherein the reducing the scaffold diameter is by no more than 40% reduction in diameter before each of the dwell breaks.2. The method of claim 1 , wherein the final diameter is at least 2.5 times less than the initial diameter.3. The method of claim 1 , wherein the polymer scaffold is a stent made from a material comprising polylactide.4. The method of claim 1 , wherein the crimping is performed by a crimping apparatus and the method additionally comprises:(a) removing the scaffold from the crimping apparatus during the reducing the scaffold diameter to adjust, if necessary, a position of the scaffold on the balloon to ensure accurate position of the scaffold on the balloon before the scaffold is crimped to the final diameter; and(b) placing the scaffold back into the crimping apparatus to resume the reducing the scaffold diameter to the final diameter.5. The method of claim 4 , wherein the adjustment of the position of the scaffold is made by aligning the scaffold between balloon markers.6. The method of claim 1 , wherein the dwell period of time is long enough to provide stress relaxation for the polymer scaffold.7. The method of claim 6 , wherein the dwell period of time is less than 185 seconds.8. The method of claim 1 , wherein the balloon is inflated ...

Cell impregnated sleeve for paracrine and other factor production

Certain embodiments according to the present invention provide sleeve devices suitable for a wide range of therapeutic uses. In accordance with certain embodiments, the therapeutic sleeve device includes a nanofiber fabric assembly, which defines a plurality of pores, and at least one layer of cells embedded in the nanofiber fabric assembly.

DEVICES AND METHODS FOR PROTECTING AGAINST NEUROMAS

The subject invention provides devices and methods for alleviating discomfort associated with neuroma formation. The devices and methods of the invention effectively use the body's natural response of reconstructing implanted biomaterials to minimize the size of, isolate, and protect a neuroma. In preferred embodiments, the subject device is a cylindrical cap, wherein the internal chamber of the cylindrical cap physically partitions the nerve to enable an arrangement of nerve fibers (as opposed to haphazardly arranged nerve fibers often produced in neuromas). Tabs arranged on the outside of the cap can be used to manipulate the cap into place on a nerve. The open end can also be configured with flaps that can be used to widen the open end for easier insertion of the nerve into the cap. In addition, the cap's material remodels into a tissue cushion after implantation, which protects the neuroma from being stimulated and inducing pain. 120-. (canceled)21. A cap comprising: a single opening located at the proximal end of the body;', 'an internal chamber defined by the body and extending from the proximal end towards the distal end;', 'at least one divider within the internal chamber that subdivides at least a portion of the internal chamber at a distal end of the chamber; and', 'a retaining cavity between the single opening at the proximal end and the at least one divider., 'a body having a distal end and a proximal end, wherein the body comprises22. The cap of claim 21 , wherein the body comprises a biomaterial that is configured to remodel around a terminal nerve end to form a tissue cushion.23. The cap of claim 21 , wherein the at least one divider divides the internal chamber into two or more separate channels claim 21 , and wherein the divider comprises a biomaterial configured to remodel around the two or more separate channels to form a tissue cushion between the subdivided portions of the internal chamber.24. The cap of claim 21 , wherein the cap comprises a ...

Automated Stent Coating Apparatus and Method

An automated apparatus and method for coating medical devices such as an intravascular stent, are disclosed in the method, a 2-D image of a stent is processed to determine (1) paths along the stent skeletal elements by which a stent secured to a rotating support element can be traversed by a dispenser head whose relative motion with respect to the support element is along the support-element axis, such that some or all of the stent skeletal elements will be traversed (2) the relative speeds of the dispenser head and support element as the dispenser head travels along the paths, and (3), and positions of the dispenser head with respect to a centerline of the stent elements as the dispenser head travels along such paths The rotational speed of the support and relative linear speed of the dispenser are controlled to achieve the desired coating thickness and coating coverage on the upper surfaces, and optionally, the side surfaces, of the stem elements 1. Apparatus for creating a coating on the outer surface of a stent whose tubular structure is composed of linked skeletal elements , comprising(a) a support element adapted to support such a stent during a coating operation,(b) a dispenser having an dispensing head through which coating material can be applied in liquid form, at a selected rate, as the dispensing head moves relative to the support element,(c) first and second electromechanical devices for (i) synchronously rotating the support element at a selected rotational speed, and (ii) moving the dispensing head relative to the support element in a direction along said support element axis, respectively,(d) an imaging system adapted to capture a representation of such a stent, and(e) a control unit operatively connected to the imaging system and to the first and the second electromechanical devices for:(e1) processing the representation obtained with the imaging system to determine (i) paths along the stent skeletal elements by which a stent secured to the support ...

Methods and systems for stiffening of tissue for improved processing

Methods and systems for stiffening of tissue are presented to allow improved processing. Solutions comprising an acid or a base can be contacted with tissue to stiffen one or more components of the tissue. The resulting stiffened tissue can be used in the creation of wound treatment devices.

Device with an Open Cell Element

A medical device comprises an elongated member. The medical device comprises a hole forming surface along a portion of the elongated member. The medical device comprises an open cell element in physical communication with the elongated member. The open cell element is configured to house at least a first portion of a biocompatible substance. 1. A medical device comprising:a) an elongated member;b) a hole forming surface along a portion of the elongated member; andc) an open cell element in physical communication with the elongated member, the open cell element configured to house at least a first portion of a biocompatible substance.2. The medical device according to claim 1 , wherein the elongated member comprises a solid material.3. The medical device according to claim 1 , wherein the medical device is configured to be employed as one of the following:a) a drill bit;b) a tap;c) a punch;d) a burr;e) a file;f) a cutter;g) a shaver;h) a cannula;i) a probe;j) a retractor; andk) a stitching needle.4. The medical device according to claim 1 , wherein the hole forming surface comprises a first material claim 1 , and the open cell element comprises a second material.5. The medical device according to claim 4 , wherein at least one of the first material and the second material comprises surgical stainless steel.6. The medical device according to claim 4 , wherein at least one of the first material and the second material comprises porous stainless steel.7. The medical device according to claim 1 , wherein the hole forming surface comprises a first porosity claim 1 , and the open cell element comprises a second porosity.8. The medical device according to claim 1 , wherein the elongated member comprises a well claim 1 , the well surrounded by the open cell element and configured to house at least a second portion of the biocompatible substance.9. The medical device according to claim 1 , wherein at least some of the biocompatible substance is dry.10. The medical device ...

A growth factor and extracellular vesicle frozen or powdered additive comprising a mesenchymal stem cell (msc) preparation and methods of use

Disclosed are mesenchymal stem cell growth factor compositions and methods of their use to treat skin disorder, alleviate the effects of aging, treat wounds, orthopedic disorders, sexual dysfunction and/or reduce inflammation.

Medical Devices for Delivering a Bioactive to a Point of Treatment and Methods of Making Medical Devices

Methods of making medical devices are described. A method of making a medical device for delivering a bioactive includes preparing a suitable solution comprising the bioactive; placing a vessel containing the solution over a substrate comprising a biocompatible foam and defining open cells; initiating flow of the solution from the vessel and toward the substrate such that the solution exits the vessel and contacts the substrate; and maintaining flow of the solution for an amount of time sufficient to achieve a desired volume of the solution within the substrate. Medical devices made by the methods are also described. 1. A method of making a medical device for delivering a bioactive , said method comprising:preparing a suitable water-based solution comprising said bioactive;placing a vessel containing the solution over a substrate comprising a biocompatible foam formed of an expanded natural material and defining a plurality of cells;initiating flow of the solution from the vessel and toward the substrate such that the solution exits the vessel and contacts the substrate;massaging the substrate to facilitate entry of the solution into the substrate; andmaintaining flow of the solution for an amount of time sufficient to achieve a desired volume of the solution within the substrate.2. The method of claim 1 , wherein the substrate comprises a biocompatible foam formed of an expanded collagenous material.3. The method of claim 1 , wherein the substrate comprises a biocompatible foam formed of an expanded extracellular matrix material.4. The method of claim 1 , wherein the substrate comprises a biocompatible foam formed of expanded small intestine submucosa.5. The method of claim 1 , wherein the massaging the substrate comprises contacting a portion of the substrate that contains the solution with a finger and moving the finger across the substrate while maintaining contact between the finger and the substrate.6. The method of claim 1 , wherein the massaging comprises ...

Methods And Compositions For The Treatment Of Open And Closed Wound Spinal Cord Injuries

Devices and methods for the treatment of open and closed wound spinal cord injuries are disclosed. For example, described herein are devices and methods for mitigating secondary injury to, and promoting recovery of, spinal cord primary injuries. More particularly, certain embodiments of the present invention are directed to polymeric mini-tubes that may be used for the treatment of spinal cord injuries. In addition, other embodiments are directed to polymeric “fill-in” bandages that may be used for the treatment of spinal cord injuries. For example, an erodible, or biodegradable, form of biocompatible polymer of the present invention is fabricated for surgical implantation into the site of the spinal cord injury. 145-. (canceled)46. A method of treating a compression and/or contusion spinal cord injury in an animal comprising the steps of:(a) providing a suitably sized biodegradable and/or bioabsorbable polymeric article for implanting within a necrotic lesion of the spinal cord parenchyma tissue, wherein the polymeric article comprises a single layer scaffold; and(b) implanting the polymeric article within the lesion to bridge a gap in the spinal cord parenchymal tissue formed by said lesion wherein once implanted said polymeric article is not exposed to the environment outside the spinal cord.47. The method of claim 46 , wherein said polymeric article comprises a single layer linear aliphatic polyester scaffold.48. The method of claim 47 , wherein the linear aliphatic polyester is a polyglycolide or a co-polymer of poly(glycolide-co-lactide).49. The method of claim 46 , wherein the polymeric article degrades in vivo in 30 to 60 days.50. The method of claim 46 , wherein the polymeric article is a cylinder.51. The method of claim 46 , wherein the polymeric article is moldable.52. The method of claim 46 , wherein the polymeric article is tubular.53. The method of claim 46 , wherein the polymeric article further comprises one or more medicinal agents deposited onto ...

METHODS FOR PREPARING DRY CROSS-LINKED TISSUE

A method of preparing dry cross-linked biological tissue. A processing solution is prepared that contains a cross-linking agent and an organic water-soluble liquid. Biological tissue is immersed in the processing solution for an effective period of time to substantially displace water from the biological tissue and substantially cross-link the biological tissue to form dry cross-linked biological tissue. 1. A method of preparing dry cross-linked biological tissue comprising:preparing a processing solution that comprises a cross-linking agent and an organic water-soluble liquid; andimmersing a biological tissue in the processing solution for an effective period of time to substantially displace water from the biological tissue and substantially cross-link the biological tissue to form dry cross-linked biological tissue.2. The method of claim 1 , wherein the cross-linking agent is provided in the processing solution at a concentration of between about 0.10 percent by weight and about 1.00 percent by weight.3. The method of claim 1 , wherein the cross-linking agent comprises at least one of an amine- and a carboxyl-reactive crosslinker.4. The method of claim 1 , wherein the cross-linking agent includes glutaraldehyde.51070. The method of claim 1 , wherein the organic water-soluble liquid is provided in the processing solution at a concentration of between about percent by volume and about percent by volume.6. The method of claim 1 , wherein the organic water-soluble liquid comprises at least one polyhydric alcohol.7. The method of claim 1 , wherein the organic water-soluble liquid includes at least one of glycerol claim 1 , sucrose claim 1 , propylene glycol claim 1 , triethylene glycol claim 1 , and tetraethylene glycol.8. The method of claim 1 , wherein the processing solution is saline buffered.9. The method of claim 1 , wherein the biological tissue is fresh prior to being immersed in the processing solution.10. The method of claim 1 , wherein the effective period ...

TISSUE MATRICES AND METHODS OF TREATMENT

Methods and devices for treatment of tissues are provided. The methods can be used to interlock a composition with tissue for protection or engagement of the tissue. The devices can be used to treat a number of treatment sites, for example, to provide structural support to injured or surgically altered tissues and/or to secure tissues and/or implants in place. 1. A method of treatment , comprising:providing a composition, the composition including (i) a first portion including a first portion body, (ii) a first interlocking component formed in the first portion body, (iii) a second portion including a second portion body, and (iv) a second interlocking component formed in the second portion body;at least partially wrapping around or positioning the first portion onto a first side of an implant;at least partially wrapping around or positioning the second portion onto a second side of the implant; anddetachably interlocking the first interlocking component of the first portion relative to the second interlocking component of the second portion to maintain the composition at least partially wrapped around or positioned on the implant.2. The method of claim 1 , wherein the second portion is formed as a separate component from the first portion.3. The method of claim 1 , wherein the composition comprises at least one of a tissue matrix or a synthetic material.4. The method of claim 1 , wherein the first interlocking component comprises a tab including two opposing extensions.5. The method of claim 1 , wherein the second interlocking component comprises an opening passing through the second portion.6. The method of claim 1 , wherein the second interlocking component comprises one or more holes or slits passing through the second portion.7. The method of claim 1 , wherein the first portion is configured to remain interlocked relative to the second portion without the use of suture.8. The method of claim 1 , wherein the first portion body defines a semicircular ...